A Phase 2 interventional study of Eltrombopag olamine and Placebo in Thrombocytopaenia, sponsored by GlaxoSmithKline. Completed at 86 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-04-18.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies testing eltrombopag in Thrombocytopenia — 2 open to participants now, 3 under way, none of them phase 3. eltrombopag · Thrombocytopenia.
Among the 53 studies testing eltrombopag in Thrombocytopenia, this one is the 10th largest by enrollment, is one of 4 that started in 2010, is one of 27 in phase 2, and was the 20th registered.
484 studies on the registry are indexed under Thrombocytopenia; 102 are open to participants now.
Browse Thrombocytopenia studies →2 of the 53 studies testing eltrombopag in Thrombocytopenia are open now, in 2 countries. Recruiting first, the newest first:
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18+
National Heart, Lung, and Blood Institute (NHLBI) · Sites in United States
Ages 3–99
By country, each count listing its studies:
eltrombopag: first FDA approval 2008 (PROMACTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 66 Thrombocytopenia studies recruiting now, 44 (67%) set no upper age limit and 18 (27%) stop at 75 or younger; 10 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 33 · Phase 3 13 · Phase 4 3
First in 2005; this study’s year is marked. 4 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 130 is above the median of 54 across 336 interventional studies indexed under Thrombocytopenia.
Median enrollment 40 across the 53 interventional studies. Of the 45 that completed or were terminated, 25 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 53 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
21 studies in Thrombocytopenia by GlaxoSmithKline: none open now, none under way, none of them phase 3. Of 20 finished, 9 (45%) have results posted.
Among the 21 studies in Thrombocytopenia by GlaxoSmithKline, this one is the 4th largest by enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2010, is one of 6 in phase 2, and was the 14th registered.
GlaxoSmithKline’s Thrombocytopenia studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 53 studies testing eltrombopag in Thrombocytopenia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 21 in Thrombocytopenia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The present study is a randomized, blinded, placebo-controlled, two-Phase, sequential cohort, dose finding study to assess the safety and efficacy of eltrombopag in patients with solid tumors receiving gemcitabine monotherapy or the combination of gemcitabine plus carboplatin or cisplatin. Phase I of the study will examine safety and tolerability of various doses of eltrombopag to identify a dose and schedule of eltrombopag. Phase II will confirm that the chosen dose and schedule of eltrombopag from Phase I can deliver clinically meaningful benefit(s) to thrombocytopenic patients by improving platelet numbers.
Inclusion Criteria:Inclusion Criteria Subjects eligible for enrolment in Phase I and II of the study must meet all of the following criteria:
For Phase II (Part 1 and 2): Subjects must meet one of the following platelet count entry criteria:
Serum ≤1.5 x and ALT
Exclusion Criteria:
Subjects meeting any of the following criteria must not be enrolled in the study:
Note: if subject has performed a CT scan immediately prior to the screening period and CT could not be repeated, an MRI should be performed in the screening period to exclude the development of brain metastases and/or the progression of the pre-existing brain metastatic lesion(s).
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: eltrombopag olamine thrombopoietin receptor agonist
Drug: Eltrombopag olamine
Other: Placebo Placebo tablets with no active pharmaceutical ingredient
Other: Placebo
thrombopoietin receptor agonist
Placebo tablets with no active pharmaceutical ingredient
Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I
AEs are coded using the standard Medical Dictionary for Regulatory Activities (MedDRA) and were graded by the investigator according to National Cancer Institute (NCI) Common Terminology Criteria for AEs (CTCAE), version 4.0. AE is any untoward medical occurrence temporally associated with the use of a medicinal product (MP), whether or not considered related to the MP. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a MP. For marketed MPs, this also includes failure to produce expected benefits, abuse, or misuse. SAE event is any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or, is a congenital anomaly/birth defect.
Time frame: From Cycle 1, Day 1 (C1D1) until at least 30 days post-investigational product discontinuation (longer for AEs considered related to study participation)
Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I
Hematology parameters with a related NCI CTCAE (version 4.0) toxicity grading were summarized by toxicity grade at each scheduled assessment, the maximum toxicity grade reached by a participant post-Baseline was summarized. Hematology parameters included hemoglobin (increased), hemoglobin (anemia), lymphocytes (increased), lymphocytes (decreased), total absolute neutrophil count (ANC), platelets (PLT) and white blood cells (WBC). The Baseline value is defined as the value reported immediately prior to the administration of the first dose of chemotherapy in Cycle 1. Post-Baseline is defined as any time after the first dose of chemotherapy in Cycle 1 up to and including all follow-up visits. Only those participant available at the indicated time points were analyzed (represented by n=X,X,X,X in the category titles).
Time frame: After Baseline (C1D1), on-treatment and 30 day follow-up
Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I
Clinical chemistry laboratory parameters with a related NCI CTCAE (version 4.0) toxicity grading were summarized by toxicity grade at each scheduled assessment. Clinical chemistry laboratory parameters included albumin (Alb), urea/blood urea nitrogen (BUN), creatinine, aspartate amino transferase (AST), alanine amino transferase (ALT), alkaline phosphatase (ALP), total bilirubin (TB), direct bilirubin (DB) and international normalized ratio/Prothrombin time (PT). The Baseline value is defined as the value reported immediately prior to the administration of the first dose of chemotherapy in Cycle 1. Post-Baseline is defined as any time after the first dose of chemotherapy in Cycle 1 up to and including all follow-up visits. Only those participants available at the indicated time points were analyzed (represented by n=X,X,X,X in the category titles).
Time frame: After Baseline (C1D1), on-treatment and 30 day follow-up
Number of Participants With a Change From Baseline in Creatinine of >=26.5 Micromoles/Liter (UMOL/L) in Phase I
The number of participants with at least 1 change from Baseline in creatinine, with an increase \>=26.5 UMOL/L are reported. Creatinine clearance is estimated using the Cockcroft-Gault formula which is a method to approximate kidney function. The Baseline value is defined as the value reported immediately prior to the administration of the first dose of chemotherapy in Cycle 1.
Time frame: After Baseline (C1D1), on-treatment and 30 day follow-up
Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I
ECOG-Zubrod scores for the performance status are defined as follows: Score 0: Fully active, 1: restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, 2: ambulatory and capable of all self-care but unable to carry out any work activities, 3: capable of only limited self-care, 4: completely disabled, 5: dead. The data is presented for the participants with the ECOG performance score at the indicated time points during the study.
Time frame: Screening, C1D1, C2D1, C2D8, C2D15, C3D1, C4D1, C4D22, C5D1, C5D8, C6D1, C6D15
Number of Participants With Electrocardiogram (ECG) Findings at Anytime Post-Baseline in Phase I
A single safety 12-lead ECG was performed using a standard 12-lead ECG machine at screening and post-dose on C2D4. Three further ECGs were carried out at C2D8, C5D8 and C6D15. Change in ECG findings were categorized as 'Clinically significant change: favorable', 'No change or insignificant change' or 'Clinically significant change (CSC): unfavorable' as determined by the investigator. The Baseline value is defined as the value reported immediately prior to the administration of the first dose of chemotherapy in Cycle 1. Any time post-Baseline is defined by counting the participants under the worst result experienced post-Baseline. The best to worst order is 'Clinically significant change: favorable', 'No change or insignificant change', and then 'Clinically significant change (CSC): unfavorable. Only those participants available at the indicated time points were analyzed (represented by n=X,X,X,X in the category titles).
Time frame: C2D4, C2D8, C5D8, C6D15
Mean Day 1 Scheduled Pre-chemotherapy Platelet Count Evaluated Across Cycles 1 to 6 in Phase II
Scheduled pre-chemotherapy platelet count is defined within each cycle as the platelet count assessment on which the decision to give or delay chemotherapy was made. This was averaged for each participant across Cycles 1 to 6 and a natural log transformation was applied to the average. The log-transformed values were compared between eltrombopag and placebo groups using an analysis of covariance (ANCOVA) model adjusting for cycle duration (21-day vs. 28-day), Baseline loge(platelet count) and part of study (part 1 or 2 of phase II). Only those participants available at indicated time points were analyzed (represented by n=X,X).
Time frame: Day 1 (averaged across cycles 1 to 6)
Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I
Pre-chemotherapy platelet count is defined for Cycle 1 as the platelet count (from central laboratory data) immediately preceding the first dose of chemotherapy within Cycle 1. For all subsequent cycles it is defined as the platelet count (from central laboratory data) immediately preceding, but limited to within 2 days prior to the first dose of chemotherapy at Day 1. For Group A, the chemotherapy cycle consisted of 21 days and for Group B, the chemotherapy cycle consisted of 28 days. Blood samples were collected to estimate platelet count at the following time points: Group A; Days 1 and 8 of Cycles 1 to 6. Group B; Days 1, 8 and 15 of Cycles 1 to 6. Only those participants available at indicated time points were analyzed (represented by n=X, X, X, X).
Time frame: C1D1, C1D8, C1D15, C2D1, C2D8, C2D15, C3D1, C3D8, C3D15, C4D1,C4D8, C4D15, C5D1,C5D8, C5D15, C6D1,C6D8 and C6D15
Average Within-subject Central Laboratory Platelet Count Prior to Scheduled Chemotherapy Across Cycles 2 to 6 in Phase I
Within-subject platelet count for each participant was calculated by summing up the visit platelet counts from each of Cycles 1 to 6 and dividing it by the number of cycles in which the participant had data. The average within a treatment group was calculated by summing up the values from each participant within the treatment group and dividing it by the number of participants. These platelet counts are different from the pre-chemotherapy platelet counts for cycles where the chemotherapy dose was delayed. Average within-subject central laboratory platelet count prior to scheduled chemotherapy across Cycles 2 to 6 are summarized. Blood samples were collected on Days 1 and 8 of Cycles 2 to 6 for Group A and on Days 1, 8 and 15 from Cycles 2 to 6 for Group B to estimate the average within subject platelet count prior to scheduled chemotherapy. Only those participants available at the indicated time points were analyzed (represented by n=X,X,X,X in the category titles).
Time frame: Day 1 (averaged across Cycles 2 to 6), Day 8 (averaged across Cycles 2 to 6)
Platelet Count Nadir for Each Chemotherapy Cycle in Phase I
Platelet nadir is defined as the lowest platelet count (from central laboratory data) reported after the first dose of chemotherapy within each cycle. Platelet count nadir is defined for each cycle. For Group A, the chemotherapy cycle consisted of 21 days and for Group B, the chemotherapy cycle consisted of 28 days. Blood samples were collected to estimate platelet nadir count at the following time points: Group A; Days 1, 4, 8, 15 and 17 of Cycles 1 and 2, at Days 1, 4, 8, 15 and 17 of Cycle 3 to 6. Group B; Days 1, 4, 8, 15, 22 and 24 of Cycles 1 to 6. Only those participants available at indicated time points were analyzed (represented by n=X, X, X, X).
Time frame: Cycle 1 to Cycle 6
Central Laboratory Average Daily Area Under the Curve Platelet-time Course Across Cycles 2 to 6 in Phase I
The average daily area under the platelet-time course was normalized by dividing the area under curve by total duration. This gives an estimated average platelet value over the time period from cycles 2 to 6. For 21-Day Cycle, the chemotherapy cycle consisted of 21 days and for 28-Day Cycle, the chemotherapy cycle consisted of 28 days. Blood samples were collected to estimate thrombocytes at the following time points: 21-Day Cycle; Days 1, 4, 8, 15 and 17 of Cycles 1 to 6. 28-Day Cycle; Days 1, 4, 8, 15, 22 and 24 of Cycles 1 to 6.
Time frame: All assessments from Cycle 2 Day 1 to last assessment in Cycle 6
Number of Participants With Thrombocytopenia of Grade 1, 2, 3 or 4 Across All the Chemotherapy Cycles in Phase I, Using Central Laboratory Platelet Count
As per the CTCAE version 4.0, par. with a platelet count \<LLN but \>=75 x 10\^9/L (Gi/L) were considered to have Grade 1 thrombocytopenia; par. with a platelet count \<75Gi/L, but \>=50Gi/L were considered to have Grade 2 thrombocytopenia; par. with a platelet count \<50Gi/L, but \>=25Gi/L were considered to have Grade 3 thrombocytopenia and par. with a platelet count \<25Gi/L were considered to have Grade 4 thrombocytopenia. Blood samples were collected to estimate thrombocytes at the following time points: For Group A, the chemotherapy cycle consisted of 21 days and for Group B, the chemotherapy cycle consisted of 28 days. Blood samples were collected to estimate thrombocytes at the following time points: Group A; Days 1, 4, 8, 15 and 17 of Cycles 1 to 6. Group B; Days 1, 4, 8, 15, 22 and 24 of Cycles 1 to 6. Par. experiencing thrombocytopenia (Platelets \<150Gi/L) at least once within a cycle are presented in the category title as n=X,X,X,X.
Time frame: Cycle 1 to Cycle 6
Maximum Duration of Thrombocytopenia Across Cycles 2 to 6 in Phase I, Estimated Using Central Laboratory Platelet Counts
Duration of thrombocytopenia is defined as a period of time in days from the first report of a platelet count with NCI CTCAE Grade 1-4 until the first subsequent report of a platelet count no longer meeting those criteria, regardless of rescue medication usage. It was assessed between Day 1 of Cycle 2 and up to and including any Conclusion/Early Withdrawal visit assigned to the same cycle for participants completing up to 6 cycles, and between Day 1 of Cycle 2 and up to and including the end of Cycle 6 for participants continuing beyond 6 cycles. The chemotherapy cycle for Group A was 21 days and for Group B was 28 days. Blood samples were collected to estimate thrombocytes at the following time points: Group A; Days 1, 4, 8, 15 and 17 of Cycles 2 to 6. Group B; Days 1, 4, 8, 15, 22 and 24 of Cycles 2 to 6.
Time frame: Cycle 2 to Cycle 6
Central Laboratory Platelet Count for Time Taken to Reach Platelet Nadir for Each Chemotherapy Cycle in Phase I
Platelet nadir is defined within each cycle as the lowest platelet count reported after the Day 1 chemotherapy dose. The time taken to reach platelet nadir is defined within each cycle. For Group A, the chemotherapy cycle consisted of 21 days and for Group B, the chemotherapy cycle consisted of 28 days. Blood samples were collected to estimate platelet nadir count at the following time points: Group A; Days 1, 4, 8, 15 and 17 of Cycles 1 to 6. Group B; Days 1, 4, 8, 15, 22 and 24 of Cycles 1 to 6. Only those participants available at indicated time points were analyzed (represented by n=X, X, X, X).
Time frame: Cycle 1 to Cycle 6
Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase I, Estimated Using Central Laboratory Platelet Counts
Platelet nadir is defined within each cycle as the lowest platelet count reported after the Day 1 chemotherapy dose. Time to recovery (TR) (\>100Gi/L or \>150Gi/L) from platelet nadir is defined within each cycle as the time in days from the platelet nadir to the time at which platelet count returns to \>=100Gi/L or \>=150Gi/L within the same cycle or up to and including Day 1 of the next cycle. For the last cycle in the study, time to recovery was calculated in the same manner but up to and including any Conclusion/Early Withdrawal visit which has been assigned to the same cycle. For Group A, the chemotherapy cycle consisted of 21 days and for Group B, the chemotherapy cycle consisted of 28 days. Blood samples were collected to estimate platelet count at: Group A; Days 1, 4, 8, 15 and 17 of Cycles 1 to 6. Group B; Days 1, 4, 8, 15, 22, and 24 of Cycles 1 to 6. Only those participants available at indicated time points were analyzed (represented by n=X, X, X, X).
Time frame: Cycle 1 to Cycle 6
Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I
Dose intensity of chemotherapy is defined as the actual dose of chemotherapy given as a percentage of the scheduled C1D1/C1D8 dose, as applicable, within this study: Cycle Dose Intensity (%) = Total Actual dose (mg/m\^2) within Cycle \*100/ Total Scheduled dose (mg/m\^2) in Cycle 1; wherein Actual Dose (mg/m\^2) = Actual dose (mg)/Body Surface Area reported on electronic case report form (eCRF).
Time frame: Cycle 1 to Cycle 6
Number of Participants With at Least One Delay in Their Scheduled Dose of Chemotherapy in Any Cycle in Phase I
Any delay in a scheduled dose of gemcitabine monotherapy or the combination of gemcitabine plus carboplatin or cisplatin was evaluated for eltrombopag and placebo treated participants.
Time frame: All time on chemotherapy treatment
Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase II
AE is any untoward medical occurrence temporally associated with the use of a medicinal product (MP), whether or not considered related to the MP. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a MP. For marketed MPs, this also includes failure to produce expected benefits, abuse, or misuse. SAE event is any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or, is a congenital anomaly/birth defect.
Time frame: From first dose of investigational product (IP) until 30 days after discontinuation of IP (Longer for AEs related to study participation)
Number of Participants With Any Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale, Across Cycles 1-6 in Phase II
The WHO Bleeding Scale is a measure of bleeding severity with the following grades: Grade 0=no bleeding; Grade 1=petechiae; Grade 2=mild blood loss; Grade 3=gross bleeding; Grade 4=debilitating blood loss. The WHO grades were further classified into the following categories: no bleeding=Grade 0; any bleeding=Grades 1 to 4; no clinically significant bleeding=Grades 0 to 1; clinically significant bleeding=Grades 2 to 4. Baseline is defined as the Day 1 assessment or the latest possible screening assessment. Across Cycles 1-6 included all assessments after first dose of chemotherapy up to the end of Cycle 6. Data exclused for participants taking drugs that affect platelet function or anticoagulants, from the time that the medication was started.
Time frame: Screening, Day -5, Day 1 and 8 of Cycles 1 to 6 of 21-day cycle schedule, Day 1, 8 and 15 of cycles 1 to 6 of 28-day schedule, treatment withdrawal and 30-day follow-up
Number of Participants Requiring a Platelet Transfusion in Phase II
Platelet transfusion was used as a rescue medication for the treatment of thrombocytopenia. Number of participants requiring a platelet transfusion during Cycles 1-6 was summarized and compared between treatment groups using a logistic regression model adjusted for cycle duration. Each cycle included assessments starting at Day 1 of the cycle.
Time frame: Screening, Day -5, throughout cycles 1 to 6 and up to 30 days after IP discontinuation
Number of Participants With at Least One Delay in Their Scheduled Dose of Chemotherapy in Any Cycle in Phase II
Any delay in scheduled dose of gemcitabine monotherapy or the combination of gemcitabine plus carboplatin or cisplatin was evaluated for eltrombopag and placebo treated participants. Number of participants with any delay in dose during 21-day cycle or 28-day cycle, in part 1 or part 2 of the study is summarized and presented. Only those participants who actually received chemotherapy are included for the cisplatin and carboplatin components and all participants are included for the gemcitabine components (represented by n=X,X in the category titles).
Time frame: Cycle 1 to Cycle 6
Number of Participants With Any Dose Reduction in Their Scheduled Dose of Chemotherapy in Any Cycle in Phase II
Dose reductions are required following potential drug-related toxicities. Number of participants with any dose reduction during 21-day cycle or 28-day cycle, in part 1 or part 2 of the study is summarized and presented. Only participants who actually received chemotherapy were included for the cisplatin and carboplatin components. All participants were included for the gemcitabine components.
Time frame: Cycle 1 to Cycle 6
Dose Intensity of Gemcitabine Plus Cisplatin(G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1-6 in Phase II
Dose intensity of chemotherapy is defined as the actual dose of chemotherapy given as a percentage of the scheduled C1D1/C1D8 dose, as applicable, within this study: cycle Dose Intensity (%) = Total Actual dose (mg/m\^2) within cycle \*100/ Total Scheduled dose (mg/m\^2) in Cycle 1; wherein Actual Dose (mg/m\^2) = Actual dose (mg)/Body Surface Area reported on eCRF. The average chemotherapy dose intensity at Day 1 across Cycles 1 to 6, Day 8 across Cycles 1 to 6 and Day 15 across Cycles 1 to 6 was summarized and compared between treatment groups using an ANCOVA model adjusted for cycle duration and part of the study.
Time frame: Cycle 1 to Cycle 6
Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II
Hematology parameters with a related NCI CTCAE (version 4.0) toxicity grading were summarized by toxicity grade at each scheduled assessment, the maximum toxicity grade reached by a participant post-Baseline was summarized. Hematology parameters included Hemoglobin (Hb) increased, Anemia, Lymphocyte count (Lym), platelet count, White Blood Cell count (WBC) and Total Absolute Neutrophil Count (Total ANC). The Baseline value is defined as the value reported immediately prior to the administration of the first dose of chemotherapy in Cycle 1. Post-Baseline is defined as any time after the first dose of chemotherapy in Cycle 1 up to and including all follow-up visits. participants with missing Baseline value were assumed to have normal Baseline value. Only those Participant available at the indicated time points were analyzed (represented by n=X,X in the category titles).
Time frame: After baseline (C1D1), on-treatment and 30 day follow-up
Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II
Clinical chemistry laboratory parameters with a related CTCAE (version 4.0) toxicity grading were summarized by toxicity grade at each scheduled assessment. Worst-case grade change of the laboratory parameters at anytime post-Baseline is presented as "Any grade increase", "Increase to Grade 3 or Grade 4". Clinical chemistry laboratory parameters included Albumin (Al), creatinine, AST, ALT, ALP, TB, Calcium hypercalcemia (CaHy)/hypocalcemia (CaHo), Glucose hyperglycemia (GluHy)/hypoglycemia (GluHo), Potassium hypernatremia (KHy)/hyponatremia (KHo) and Sodium hypernatremia (NaHy)/hyponatremia (NaHo). The Baseline value is defined as the value reported immediately prior to the administration of the first dose of chemotherapy in Cycle 1. Post-Baseline is defined as any time after the first dose of chemotherapy in Cycle 1 up to and including all follow-up visits. Only those Participant available at the indicated time points were analyzed (represented by n=X,X in the category titles).
Time frame: After baseline (C1D1), on-treatment (collected on days 1 and 8 for subjects on 21-day cycle and on days 1, 8 and 15 for subjects on 28-day cycle) and 30 day follow-up
Number of Participants With Change From Baseline in Creatinine of >=26.5 UMOL/L in Phase II
Number of participants with at least 1 assessment of change from Baseline in creatinine, with increase \>=26.5 UMOL/L are presented. The Baseline value is defined as the value reported immediately prior to the administration of the first dose of IP.
Time frame: After baseline (C1D1), on-treatment (collected on days 1 and 8 for subjects on 21-day cycle and on days 1, 8 and 15 for subjects on 28-day cycle) and 30 day follow-up
Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II
ECOG-Zubrod scores for the Performance Status were defined as follows: 0: Fully active, 1: Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, 2: Ambulatory and capable of all self-care but unable to carry out any work activities, 3: Capable of only limited self-care, 4: Completely disabled, 5 and Unknown: Dead. The data is presented for the participants with the ECOG performance score at different time points during the study. Only those participants available at the indicated time points were analyzed (represented by n=X,X in the category titles).
Time frame: Screening, C1D1, C2D1, C3D1, C4D1, C5D1, C6D1, C7D1, C8D1, C9D1, C10D1, C11D1, C12D1, C13D1, C14D1, C15D1, C16D1 and C17D1
Number of Participants With Electrocardiogram (ECG) Findings at Cycle 1 Day 4 (2 to 6 Hours Post-dose) in Phase II
A single safety 12-lead ECG was performed using a standard 12-lead ECG machine at screening and 2 to 6 hours post-dose on C1D4. Change in ECG findings were categorized as 'Clinically significant change (CSC): favorable', 'No change or insignificant change' or 'Clinically significant change (CSC): unfavorable' as determined by the investigator. The Baseline value is defined as the value reported immediately prior to the administration of the first dose of investigational product. Only those participants available at the indicated time points were analyzed (represented by n=X,X in the category titles).
Time frame: C1D4
Mean Day 8 Scheduled Pre-chemotherapy Platelet Counts Evaluated Across Cycles 1 to 6 in Phase II
Scheduled pre-chemotherapy platelet count is defined within each cycle as the platelet count assessment on which the decision to give or delay chemotherapy was made. This was averaged for each subject across cycles 1 to 6 and a natural log transformation was applied to the average. The log-transformed values were compared between eltrombopag and placebo groups using an analysis of covariance (ANCOVA) model adjusting for cycle duration (21-day vs. 28-day), baseline loge(platelet count) and part of study (part 1 or 2 of phase II). The number of participants analyzed is the number with a Day 8 scheduled platelet count.
Time frame: Day 8 (averaged across cycles 1 to 6)
Mean Day 15 Scheduled Pre-chemotherapy Platelet Counts Evaluated Across Cycles 1 to 6 in Phase II
Scheduled pre-chemotherapy platelet count is defined within each cycle as the platelet count assessment on which the decision to give or delay chemotherapy was made. This was averaged for each subject across cycles 1 to 6 and a natural log transformation was applied to the average. The log-transformed values were compared between eltrombopag and placebo groups using an analysis of covariance (ANCOVA) model adjusting for cycle duration (21-day vs. 28-day), baseline loge(platelet count) and part of study (part 1 or 2 of phase II). The number of participants analyzed is the number with a Day 15 scheduled platelet count.
Time frame: Day 15 (averaged across cycles 1 to 6)
Mean Within-subject Platelet Count Prior to Scheduled Chemotherapy Across Cycles 1 to 6 in Phase II
Within-subject platelet count for each par. was calculated by summing up the visit platelet counts from each of Cycles 1 to 6 and dividing it by the number of cycles in which the par. had data. The average within a treatment group was calculated by summing up the values from each par. within the treatment 21-day cycle dividing it by the number of par. These platelet counts are different from the pre-chemotherapy platelet counts for cycles where the chemotherapy dose was delayed. Average within-subject central laboratory platelet count prior to scheduled chemotherapy across Cycles 1 to 6 are summarized. Blood samples were collected on Day 1 and 8 of Cycles 1 to 6 for 21-day cycle and on Day 1, 8 and 15 from Cycles 1 to 6 for 28-day cycle to estimate the average within subject platelet count prior to scheduled chemotherapy. Only those participants available at the indicated time points were analyzed (represented by n=X,X in the category titles).
Time frame: Day 1, Day 8, Day 15 (all averaged across cycles 1 to 6)
Platelet Count Nadir for Each Chemotherapy Cycle in Phase II
Platelet nadir is defined as the lowest platelet count reported after the first dose of chemotherapy within each cycle. Platelet count nadir is defined for each cycle. Blood samples were collected to estimate platelet nadir count at the following time points: 21-day cycle; Day 1, Day 4, Day 8, Day 15 and Day 17 of Cycles 1 to 6. 28-day cycle; Day 1, Day 4, Day 8, Day 15, Day 22, Day 24 of Cycles 1 to 6. Only those participants available at indicated time points were analyzed (represented by n=X, X).
Time frame: Cycle 1 to Cycle 6
Average Daily Area Under the Platelet-time Course Across Cycles 1 to 6 in Phase II
The average daily area under the platelet-time course was normalized by dividing the area under curve by total duration. This gives an estimated average platelet value over the time period from cycles 1 to 6. Blood samples were collected to estimate platelet count at the following time points: 21-day cycle; Days 1, 4, 8, 15 and 17 of Cycles 1 to 6. 28-day cycle; Days 1, 4, 8, 15, 22 and 24 of Cycles 1 to 6.
Time frame: All assessments from Cycle 1 Day 1 to last assessment in Cycle 6
Number of Participants With Thrombocytopenia of Grade 1, 2, 3 or 4 Across Cycles 1 to 6 in Phase II
As per the CTCAE version 4.0, participants with a platelet count \<LLN but \>=75 x 10\^9/L (Gi/L) were considered to have Grade 1 thrombocytopenia; participants with a platelet count \<75Gi/L, but \>=50Gi/L were considered to have Grade 2 thrombocytopenia; participants with a platelet count \<50Gi/L, but \>=25Gi/L were considered to have Grade 3 thrombocytopenia and participants with a platelet count \<25Gi/L were considered to have Grade 4 thrombocytopenia. Blood samples were collected to estimate thrombocytes at the following time points: 21-day cycle; Days 1, 4, 8, 15 and 17 of Cycles 1 to 6. 28-day cycle; Days 1, 4, 8, 15, 22 and 24 of Cycles 1 to 6. Participants experiencing thrombocytopenia(Platelets \<150Gi/L) at least once within cycle are presented in the category title as n=X,X.
Time frame: Cycle 1 to Cycle 6
Maximum Duration of Thrombocytopenia Across Cycles 1 to 6 in Phase II
Duration of thrombocytopenia is defined as a period of time in days from the first report of a platelet count with NCI CTCAE Grade 1-4 until the first subsequent report of a platelet count no longer meeting those criteria, regardless of rescue medication usage. It was assessed between Day 1 of Cycle 2 and up to and including any Conclusion/Early Withdrawal visit assigned to the same cycle for participants completing up to 6 cycles, and between Day 1 of Cycle 2 and up to and including the end of Cycle 6 for participants continuing beyond 6 cycles. The chemotherapy cycle for 21-day cycle was 21 days and for 28-day cycle was 28 days. Blood samples were collected to estimate thrombocytes at the following time points: 21-day cycle; Days 1, 4, 8, 15 and 17 of Cycles 2 to 6. 28-day cycle; Days 1, 4, 8, 15, 22 and 24 of Cycles 2 to 6.
Time frame: Cycle 1 to Cycle 6
Time Taken to Reach Platelet Nadir for Each Chemotherapy Cycle in Phase II
Platelet nadir is defined within each cycle as the lowest platelet count reported after the Day 1 chemotherapy dose. The time taken to reach platelet nadir is defined within each cycle. Blood samples were collected to estimate platelet nadir count at the following time points: 21-day cycle; Days 1, 4, 8, 15 and 17 of Cycles 1 to 6. 28-day cycle; Days 1, 4, 8, 15, 22 and 24 of Cycles 1 to 6. Only those participants available at indicated time points were analyzed (represented by n=X, X).
Time frame: Cycle 1 to Cycle 6
Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase II
Platelet nadir is defined within each cycle as the lowest platelet count reported after the Day 1 chemotherapy dose. TR (\>100Gi/L or \>150Gi/L) from platelet nadir is defined within each cycle as the time in days from the platelet nadir to the time at which platelet count returns to \>=100Gi/L or \>=150Gi/L within the same cycle or up to and including Day 1 of the next cycle. For the last cycle in the study, time to recovery was calculated in the same manner but up to and including any Conclusion/Early Withdrawal visit which has been assigned to the same cycle. Blood samples were collected to estimate platelet count at: 21-day cycle; Days 1, 4, 8, 15 and 17 of Cycles 1 to 6. 28-day cycle; Days 1, 4, 8, 15, 22, and 24of Cycles 1 to 6. Time to recover censored if platelet count did not return to \>=100/150 Gi/L. Censored results are excluded from calculation of summary statistics. Only those participants available at indicated time points were analyzed (represented by n=X, X).
Time frame: Cycle 1 to Cycle 6
Participants (par.) with solid tumors receiving gemcitabine monotherapy or the combination of gemcitabine plus carboplatin or cisplatin were eligible for enrollment into the study. The study comprised of 2 phases (I \& II), with eligible par. being randomized to receive placebo or eltrombopag in each phase.
| Milestone | Phase I: 21-Day Cycle Placebo | Phase I: 21-Day Cycle Eltrombopag 100 mg | Phase I: 28-Day Cycle Placebo | Phase I: 28-Day Cycle Eltrombopag 100 mg | Phase II: Placebo | Phase II: Eltrombopag 100 mg |
|---|---|---|---|---|---|---|
| Started | 3 | 9 | 4 | 10 | 0 | 0 |
| Completed | 2 | 8 | 2 | 5 | 0 | 0 |
| Not completed | 1 | 1 | 2 | 5 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Physician decision | 0 | 1 | 2 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 3 | 0 | 0 |
| Milestone | Phase I: 21-Day Cycle Placebo | Phase I: 21-Day Cycle Eltrombopag 100 mg | Phase I: 28-Day Cycle Placebo | Phase I: 28-Day Cycle Eltrombopag 100 mg | Phase II: Placebo | Phase II: Eltrombopag 100 mg |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 23 | 52 |
| Ongoing | 0 | 0 | 0 | 0 | 1 | 0 |
| Completed | 0 | 0 | 0 | 0 | 7 | 19 |
| Not completed | 0 | 0 | 0 | 0 | 16 | 33 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 3 | 6 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 5 | 11 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 7 | 15 |
| Withdrew: Ongoing | 0 | 0 | 0 | 0 | 1 | 0 |
AEs are coded using the standard Medical Dictionary for Regulatory Activities (MedDRA) and were graded by the investigator according to National Cancer Institute (NCI) Common Terminology Criteria for AEs (CTCAE), version 4.0. AE is any untoward medical occurrence temporally associated with the use of a medicinal product (MP), whether or not considered related to the MP. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a MP. For marketed MPs, this also includes failure to produce expected benefits, abuse, or misuse. SAE event is any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or, is a congenital anomaly/birth defect.
| Participants | 21-Day Cycle Placebo | 21-Day Cycle Eltrombopag 100 mg | 28-Day Cycle Placebo | 28-Day Cycle Eltrombopag 100 mg |
|---|---|---|---|---|
| Any AE Pre-therapy | 3 | 8 | 4 | 9 |
| Any SAE Pre-therapy | 1 | 0 | 0 | 1 |
| Any AE On-therapy+30 days | 3 | 9 | 3 | 10 |
| Any SAE On-therapy+30 days | 1 | 5 | 1 | 2 |
| Any AE Post-therapy | 0 | 0 | 0 | 3 |
| Any SAE Post-therapy | 0 | 0 | 0 | 1 |
| Treatment-related AEs On-therapy+30 days | 2 | 3 | 1 | 6 |
| >=Grade 3 AEs On-therapy+30 days | 2 | 7 | 2 | 3 |
| Liver AEs On-therapy+30 days | 0 | 2 | 0 | 2 |
| Renal AEs On-therapy+30 days | 0 | 3 | 2 | 0 |
| Thromboembolic events On-therapy+30 days | 0 | 2 | 0 | 1 |
| Cardiac AEs On-therapy+30 days | 0 | 1 | 1 | 1 |
| Neutropenia On-therapy+30 days | 3 | 4 | 2 | 5 |
| Anemia On-therapy+30 days | 1 | 4 | 1 | 4 |
| Thrombocytopenia On-therapy+30 days | 2 | 3 | 3 | 3 |
| Leukopenia On-therapy+30 days | 1 | 2 | 2 | 3 |
| Thrombocytosis On-therapy+30 days | 2 | 2 | 1 | 2 |
| Platelet count increased On-therapy+30 days | 0 | 0 | 0 | 3 |
Hematology parameters with a related NCI CTCAE (version 4.0) toxicity grading were summarized by toxicity grade at each scheduled assessment, the maximum toxicity grade reached by a participant post-Baseline was summarized. Hematology parameters included hemoglobin (increased), hemoglobin (anemia), lymphocytes (increased), lymphocytes (decreased), total absolute neutrophil count (ANC), platelets (PLT) and white blood cells (WBC). The Baseline value is defined as the value reported immediately prior to the administration of the first dose of chemotherapy in Cycle 1. Post-Baseline is defined as any time after the first dose of chemotherapy in Cycle 1 up to and including all follow-up visits. Only those participant available at the indicated time points were analyzed (represented by n=X,X,X,X in the category titles).
| Participants | 21-Day Cycle Placebo | 21-Day Cycle Eltrombopag 100 mg | 28-Day Cycle Placebo | 28-Day Cycle Eltrombopag 100 mg |
|---|---|---|---|---|
| Hemoglobin (Increased), Grade 0, n=3,9,4,10 | 3 | 9 | 4 | 10 |
| Hemoglobin (Anemia), Grade 1, n=3,9,4,10 | 2 | 1 | 0 | 3 |
| Hemoglobin (Anemia), Grade 2, n=3,9,4,10 | 0 | 6 | 2 | 4 |
| Hemoglobin (Anemia), Grade 3, n=3,9,4,10 | 1 | 2 | 2 | 3 |
| Lymphocytes (Increased), Grade 0, n=3,9,4,10 | 3 | 8 | 4 | 10 |
| Lymphocytes (Increased), Grade 2, n=3,9,4,10 | 0 | 1 | 0 | 0 |
| Lymphocytes (Decreased), Grade 0, n=3,9,4,10 | 1 | 1 | 0 | 3 |
| Lymphocytes (Decreased), Grade 1, n=3,9,4,10 | 0 | 2 | 0 | 0 |
| Lymphocytes (Decreased), Grade 2, n=3,9,4,10 | 1 | 1 | 1 | 4 |
| Lymphocytes (Decreased), Grade 3, n=3,9,4,10 | 1 | 5 | 3 | 2 |
| Lymphocytes (Decreased), Grade 4, n=3,9,4,10 | 0 | 0 | 0 | 1 |
| Total ANC, Grade 0, n=1,2,1,2 | 0 | 2 | 1 | 0 |
| Total ANC, Grade 1, n=1,2,1,2 | 1 | 0 | 0 | 2 |
| PLT, Grade 0, n=3,9,4,10 | 0 | 1 | 0 | 2 |
| PLT, Grade 1, n=3,9,4,10 | 0 | 1 | 1 | 3 |
| PLT, Grade 2, n=3,9,4,10 | 0 | 3 | 1 | 3 |
| PLT, Grade 3, n=3,9,4,10 | 1 | 2 | 2 | 1 |
| PLT, Grade 4, n=3,9,4,10 | 2 | 2 | 0 | 1 |
| WBC, Grade 0, n=3,9,4,10 | 0 | 0 | 1 | 2 |
| WBC, Grade 1, n=3,9,4,10 | 0 | 1 | 0 | 2 |
| WBC, Grade 2, n=3,9,4,10 | 2 | 2 | 1 | 2 |
| WBC, Grade 3, n=3,9,4,10 | 1 | 5 | 2 | 3 |
| WBC, Grade 4, n=3,9,4,10 | 0 | 1 | 0 | 1 |
Clinical chemistry laboratory parameters with a related NCI CTCAE (version 4.0) toxicity grading were summarized by toxicity grade at each scheduled assessment. Clinical chemistry laboratory parameters included albumin (Alb), urea/blood urea nitrogen (BUN), creatinine, aspartate amino transferase (AST), alanine amino transferase (ALT), alkaline phosphatase (ALP), total bilirubin (TB), direct bilirubin (DB) and international normalized ratio/Prothrombin time (PT). The Baseline value is defined as the value reported immediately prior to the administration of the first dose of chemotherapy in Cycle 1. Post-Baseline is defined as any time after the first dose of chemotherapy in Cycle 1 up to and including all follow-up visits. Only those participants available at the indicated time points were analyzed (represented by n=X,X,X,X in the category titles).
| Participants | 21-Day Cycle Placebo | 21-Day Cycle Eltrombopag 100 mg | 28-Day Cycle Placebo | 28-Day Cycle Eltrombopag 100 mg |
|---|---|---|---|---|
| Alb, Grade 0, n=3,9,4,10 | 2 | 4 | 0 | 4 |
| Alb, Grade 1, n=3,9,4,10 | 1 | 2 | 2 | 5 |
| Alb, Grade 2, n=3,9,4,10 | 0 | 3 | 1 | 1 |
| Alb, Grade 3, n=3,9,4,10 | 0 | 0 | 1 | 0 |
| ALP, Grade 0, n=3,9,4,10 | 2 | 3 | 3 | 6 |
| ALP, Grade 1, n=3,9,4,10 | 1 | 5 | 1 | 1 |
| ALP, Grade 2, n=3,9,4,10 | 0 | 1 | 0 | 2 |
| ALP, Grade 3, n=3,9,4,10 | 0 | 0 | 0 | 1 |
| ALT, Grade 0, n=3,9,4,10 | 2 | 3 | 3 | 4 |
| ALT, Grade 1, n=3,9,4,10 | 1 | 4 | 1 | 5 |
| ALT, Grade 2, n=3,9,4,10 | 0 | 2 | 0 | 0 |
| ALT, Grade 3, n=3,9,4,10 | 0 | 0 | 0 | 1 |
| AST, Grade 0, n=3,9,4,10 | 2 | 4 | 2 | 5 |
| AST, Grade 1, n=3,9,4,10 | 1 | 3 | 2 | 3 |
| AST, Grade 2, n=3,9,4,10 | 0 | 1 | 0 | 1 |
| AST, Grade 3, n=3,9,4,10 | 0 | 1 | 0 | 1 |
| TB, Grade 0, n=3,9,4,10 | 3 | 5 | 3 | 8 |
| TB, Grade 1, n=3,9,4,10 | 0 | 2 | 0 | 0 |
| TB, Grade 2, n=3,9,4,10 | 0 | 2 | 1 | 0 |
| TB, Grade 3, n=3,9,4,10 | 0 | 0 | 0 | 2 |
| Ca (hypercalcemia), Grade 0, n=3,9,4,10 | 3 | 8 | 4 | 10 |
| Ca (hypercalcemia), Grade 1, n=3,9,4,10 | 0 | 1 | 0 | 0 |
| Ca (hypercalcemia), Grade 2, n=3,9,4,10 | 0 | 0 | 0 | 0 |
| Ca (hypercalcemia), Grade 3, n=3,9,4,10 | 0 | 0 | 0 | 0 |
| Ca (hypocalcemia), Grade 0, n=3,9,4,10 | 2 | 7 | 3 | 9 |
| Ca (hypocalcemia), Grade 1, n=3,9,4,10 | 1 | 1 | 0 | 0 |
| Ca (hypocalcemia), Grade 2, n=3,9,4,10 | 0 | 1 | 1 | 1 |
| Ca (hypocalcemia), Grade 3, n=3,9,4,10 | 0 | 0 | 0 | 0 |
| Creatinine, Grade 0, n=3,9,4,10 | 3 | 7 | 4 | 9 |
| Creatinine, Grade 1, n=3,9,4,10 | 0 | 1 | 0 | 1 |
| Creatinine, Grade 2, n=3,9,4,10 | 0 | 1 | 0 | 0 |
| Creatinine, Grade 3, n=3,9,4,10 | 0 | 0 | 0 | 0 |
| Glu (hyperglycemia), Grade 0, n=3,9,4,10 | 2 | 3 | 1 | 2 |
| Glu (hyperglycemia), Grade 1, n=3,9,4,10 | 0 | 4 | 2 | 4 |
| Glu (hyperglycemia), Grade 2, n=3,9,4,10 | 1 | 2 | 1 | 4 |
| Glu (hyperglycemia), Grade 3, n=3,9,4,10 | 0 | 0 | 0 | 0 |
| Glu (hypoglycemia), Grade 0, n=3,9,4,10 | 3 | 8 | 4 | 8 |
| Glu (hypoglycemia), Grade 1, n=3,9,4,10 | 0 | 0 | 0 | 1 |
| Glu (hypoglycemia), Grade 2, n=3,9,4,10 | 0 | 1 | 0 | 1 |
| Glu (hypoglycemia), Grade 3, n=3,9,4,10 | 0 | 0 | 0 | 0 |
| K (hyperkalemia), Grade 0, n=3,9,4,10 | 1 | 8 | 3 | 9 |
| K (hyperkalemia), Grade 1, n=3,9,4,10 | 2 | 1 | 0 | 0 |
| K (hyperkalemia), Grade 2, n=3,9,4,10 | 0 | 0 | 1 | 1 |
| K (hyperkalemia), Grade 3, n=3,9,4,10 | 0 | 0 | 0 | 0 |
| K (hypokalemia), Grade 0, n=3,9,4,10 | 2 | 5 | 3 | 7 |
| K (hypokalemia), Grade 1, n=3,9,4,10 | 1 | 3 | 1 | 3 |
| K (hypokalemia), Grade 2, n=3,9,4,10 | 0 | 0 | 0 | 0 |
| K (hypokalemia), Grade 3, n=3,9,4,10 | 0 | 1 | 0 | 0 |
| Na (hypernatremia), Grade 0, n=3,9,4,10 | 2 | 9 | 3 | 10 |
| Na (hypernatremia), Grade 1, n=3,9,4,10 | 1 | 0 | 1 | 0 |
| Na (hypernatremia), Grade 2, n=3,9,4,10 | 0 | 0 | 0 | 0 |
| Na (hypernatremia), Grade 3, n=3,9,4,10 | 0 | 0 | 0 | 0 |
| Na (hyponatremia), Grade 0, n=3,9,4,10 | 2 | 4 | 2 | 5 |
| Na (hyponatremia), Grade 1, n=3,9,4,10 | 1 | 4 | 0 | 5 |
| Na (hyponatremia), Grade 2, n=3,9,4,10 | 0 | 0 | 0 | 0 |
| Na (hyponatremia), Grade 3, n=3,9,4,10 | 0 | 1 | 2 | 0 |
The number of participants with at least 1 change from Baseline in creatinine, with an increase \>=26.5 UMOL/L are reported. Creatinine clearance is estimated using the Cockcroft-Gault formula which is a method to approximate kidney function. The Baseline value is defined as the value reported immediately prior to the administration of the first dose of chemotherapy in Cycle 1.
| Participants | 21-Day Cycle Placebo | 21-Day Cycle Eltrombopag 100 mg | 28-Day Cycle Placebo | 28-Day Cycle Eltrombopag 100 mg |
|---|---|---|---|---|
| Number of Participants With a Change From Baseline in Creatinine of >=26.5 Micromoles/Liter (UMOL/L) in Phase I | 0 | 3 | 1 | 2 |
ECOG-Zubrod scores for the performance status are defined as follows: Score 0: Fully active, 1: restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, 2: ambulatory and capable of all self-care but unable to carry out any work activities, 3: capable of only limited self-care, 4: completely disabled, 5: dead. The data is presented for the participants with the ECOG performance score at the indicated time points during the study.
| Participants | 21-Day Cycle Placebo | 21-Day Cycle Eltrombopag 100 mg | 28-Day Cycle Placebo | 28-Day Cycle Eltrombopag 100 mg |
|---|---|---|---|---|
| Screening, Score 0, n=3,9,4,10 | 3 | 5 | 1 | 3 |
| Screening, Score 1, n=3,9,4,10 | 0 | 3 | 3 | 7 |
| Screening, Score 2, n=3,9,4,10 | 0 | 1 | 0 | 0 |
| Screening, Score 3, n=3,9,4,10 | 0 | 0 | 0 | 0 |
| C1D1, Score 0, n=3,9,4,10 | 3 | 5 | 2 | 3 |
| C1D1, Score 1, n=3,9,4,10 | 0 | 3 | 2 | 7 |
| C1D1, Score 2, n=3,9,4,10 | 0 | 1 | 0 | 0 |
| C1D1, Score 3, n=3,9,4,10 | 0 | 0 | 0 | 0 |
| C2D1, Score 0, n=3,8,4,10 | 1 | 3 | 2 | 2 |
| C2D1, Score 1, n=3,8,4,10 | 1 | 4 | 1 | 8 |
| C2D1, Score 2, n=3,8,4,10 | 1 | 1 | 1 | 0 |
| C2D1, Score 3, n=3,8,4,10 | 0 | 0 | 0 | 0 |
| C2D8, Score 0, n=1,0,1,0 | 1 | NA | 0 | NA |
| C2D8, Score 1, n=1,0,1,0 | 0 | NA | 0 | NA |
| C2D8, Score 2, n=1,0,1,0 | 0 | NA | 1 | NA |
| C2D8, Score 3, n=1,0,1,0 | 1 | NA | 0 | NA |
| C2D15, Score 0, n=0,1,0,1 | NA | 0 | NA | 0 |
| C2D15, Score 1, n=0,1,0,1 | NA | 0 | NA | 1 |
| C2D15, Score 2, n=0,1,0,1 | NA | 1 | NA | 0 |
| C2D15, Score 3, n=0,1,0,1 | NA | 0 | NA | 0 |
| C3D1, Score 0, n=2,6,2,7 | 1 | 2 | 2 | 4 |
| C3D1, Score 1, n=2,6,2,7 | 1 | 2 | 0 | 3 |
| C3D1, Score 2, n=2,6,2,7 | 0 | 1 | 0 | 0 |
| C3D1, Score 3, n=2,6,2,7 | 0 | 1 | 0 | 0 |
| C4D1, Score 0, n=2,6,1,7 | 1 | 1 | 0 | 4 |
| C4D1, Score 1, n=2,6,1,7 | 1 | 3 | 1 | 3 |
| C4D1, Score 2, n=2,6,1,7 | 0 | 1 | 0 | 0 |
| C4D1, Score 3, n=2,6,1,7 | 0 | 1 | 0 | 0 |
| C4D22, Score 0, n=0,0,0,1 | NA | NA | NA | 0 |
| C4D22, Score 1, n=0,0,0,1 | NA | NA | NA | 0 |
| C4D22, Score 2, n=0,0,0,1 | NA | NA | NA | 1 |
| C4D22, Score 3, n=0,0,0,1 | NA | NA | NA | 0 |
| C5D1, Score 0, n=1,3,1,4 | 0 | 0 | 0 | 2 |
| C5D1, Score 1, n=1,3,1,4 | 1 | 1 | 1 | 2 |
| C5D1, Score 2, n=1,3,1,4 | 0 | 1 | 0 | 0 |
| C5D1, Score 3, n=1,3,1,4 | 0 | 1 | 0 | 0 |
| C5D8, Score 0, n=0,1,0,0 | NA | 0 | NA | NA |
| C5D8, Score 1, n=0,1,0,0 | NA | 0 | NA | NA |
| C5D8, Score 2, n=0,1,0,0 | NA | 0 | NA | NA |
| C5D8, Score 3, n=0,1,0,0 | NA | 1 | NA | NA |
| C6D1, Score 0, n=1,1,1,4 | 0 | 1 | 0 | 2 |
| C6D1, Score 1, n=1,1,1,4 | 1 | 0 | 1 | 2 |
| C6D1, Score 2, n=1,1,1,4 | 0 | 0 | 0 | 0 |
| C6D1, Score 3, n=1,1,1,4 | 0 | 0 | 0 | 0 |
| C6D15, Score 0, n=0,0,0,1 | NA | NA | NA | 0 |
| C6D15, Score 1, n=0,0,0,1 | NA | NA | NA | 1 |
| C6D15, Score 2, n=0,0,0,1 | NA | NA | NA | 0 |
| C6D15, Score 3, n=0,0,0,1 | NA | NA | NA | 0 |
A single safety 12-lead ECG was performed using a standard 12-lead ECG machine at screening and post-dose on C2D4. Three further ECGs were carried out at C2D8, C5D8 and C6D15. Change in ECG findings were categorized as 'Clinically significant change: favorable', 'No change or insignificant change' or 'Clinically significant change (CSC): unfavorable' as determined by the investigator. The Baseline value is defined as the value reported immediately prior to the administration of the first dose of chemotherapy in Cycle 1. Any time post-Baseline is defined by counting the participants under the worst result experienced post-Baseline. The best to worst order is 'Clinically significant change: favorable', 'No change or insignificant change', and then 'Clinically significant change (CSC): unfavorable. Only those participants available at the indicated time points were analyzed (represented by n=X,X,X,X in the category titles).
| Participants | 21-Day Cycle Placebo | 21-Day Cycle Eltrombopag 100 mg | 28-Day Cycle Placebo | 28-Day Cycle Eltrombopag 100 mg |
|---|---|---|---|---|
| No change or insignificant change n=3,9,3,8 | 3 | 8 | 3 | 7 |
| CSC: unfavorable, n=3,9,3,8 | 0 | 1 | 0 | 1 |
Scheduled pre-chemotherapy platelet count is defined within each cycle as the platelet count assessment on which the decision to give or delay chemotherapy was made. This was averaged for each participant across Cycles 1 to 6 and a natural log transformation was applied to the average. The log-transformed values were compared between eltrombopag and placebo groups using an analysis of covariance (ANCOVA) model adjusting for cycle duration (21-day vs. 28-day), Baseline loge(platelet count) and part of study (part 1 or 2 of phase II). Only those participants available at indicated time points were analyzed (represented by n=X,X).
| Giga (10^9) cells per liter (Gi/L) | Placebo | Eltrombopag 100 mg |
|---|---|---|
| Mean Day 1 Scheduled Pre-chemotherapy Platelet Count Evaluated Across Cycles 1 to 6 in Phase II | 193.34 ± 54.5 | 246.20 ± 49.8 |
Pre-chemotherapy platelet count is defined for Cycle 1 as the platelet count (from central laboratory data) immediately preceding the first dose of chemotherapy within Cycle 1. For all subsequent cycles it is defined as the platelet count (from central laboratory data) immediately preceding, but limited to within 2 days prior to the first dose of chemotherapy at Day 1. For Group A, the chemotherapy cycle consisted of 21 days and for Group B, the chemotherapy cycle consisted of 28 days. Blood samples were collected to estimate platelet count at the following time points: Group A; Days 1 and 8 of Cycles 1 to 6. Group B; Days 1, 8 and 15 of Cycles 1 to 6. Only those participants available at indicated time points were analyzed (represented by n=X, X, X, X).
| Giga (10^9) cells per liter (G cells/L) | 21-Day Cycle Placebo | 21-Day Cycle Eltrombopag 100 mg | 28-Day Cycle Placebo | 28-Day Cycle Eltrombopag 100 mg |
|---|---|---|---|---|
| C1 D1, n=3,9,4,9 | 239.3 ± 75.87 | 244.8 ± 48.47 | 223.8 ± 79.96 | 207.7 ± 65.51 |
| C1 D8, n=3,6,3,9 | 180.7 ± 65.03 | 143.8 ± 33.88 | 144.0 ± 44.17 | 135.6 ± 52.52 |
| C1 D15, n=0,0,2, 6 | NA ± NA | NA ± NA | 135.0 ± 84.85 | 97.5 ± 39.15 |
| C2 D1, n=2,9,4,8 | 443.0 ± 168.29 | 545.8 ± 131.66 | 284.8 ± 84.11 | 473.3 ± 117.07 |
| C2 D8, n=2,7,3,9 | 221.0 ± 94.75 | 335.6 ± 134.06 | 163.3 ± 35.30 | 333.0 ± 146.59 |
| C2 D15, n=0,0,2,6 | NA ± NA | NA ± NA | 80.5 ± 0.71 | 142.7 ± 63.14 |
| C3 D1, n=2,5,2,7 | 464.0 ± 36.77 | 484.6 ± 188.16 | 290.5 ± 180.31 | 435.4 ± 145.57 |
| C3 D8, n=2,6,2,5 | 285.0 ± 39.60 | 292.2 ± 161.11 | 293.0 ± 199.40 | 465.2 ± 260.20 |
| C3 D15, n=0,0,2,5 | NA ± NA | NA ± NA | 92.0 ± 45.25 | 183.4 ± 119.12 |
| C4 D1, n=1,6,1,6 | 298.0 ± NA | 394.7 ± 154.28 | 609.0 ± NA | 388.3 ± 166.07 |
| C4 D8, n=1,5,1,6 | 261.0 ± NA | 249.8 ± 122.29 | 335.0 ± NA | 366.5 ± 143.75 |
| C4 D15, n=0,0,1,6 | NA ± NA | NA ± NA | 86.0 ± NA | 169.8 ± 120.56 |
| C5 D1, n=1,2,1,4 | 245.0 ± NA | 529.5 ± 340.12 | 337.0 ± NA | 406.0 ± 174.89 |
| C5 D8, n=1,1,1,4 | 144.0 ± NA | 123.0 ± NA | 311.0 ± NA | 403.5 ± 195.31 |
| C5 D15, n=0,0,1,4 | NA ± NA | NA ± NA | 75.0 ± NA | 140.5 ± 42.93 |
| C6 D1, n=1,1,1,3 | 512.0 ± NA | 123.0 ± NA | 440.0 ± NA | 360.3 ± 133.45 |
| C6 D8, n=1,1,0,3 | 251.0 ± NA | 137.0 ± NA | NA ± NA | 428.0 ± 210.71 |
| C6 D15, n=0,0,1,2 | NA ± NA | NA ± NA | 113.0 ± NA | 101.0 ± 48.08 |
Within-subject platelet count for each participant was calculated by summing up the visit platelet counts from each of Cycles 1 to 6 and dividing it by the number of cycles in which the participant had data. The average within a treatment group was calculated by summing up the values from each participant within the treatment group and dividing it by the number of participants. These platelet counts are different from the pre-chemotherapy platelet counts for cycles where the chemotherapy dose was delayed. Average within-subject central laboratory platelet count prior to scheduled chemotherapy across Cycles 2 to 6 are summarized. Blood samples were collected on Days 1 and 8 of Cycles 2 to 6 for Group A and on Days 1, 8 and 15 from Cycles 2 to 6 for Group B to estimate the average within subject platelet count prior to scheduled chemotherapy. Only those participants available at the indicated time points were analyzed (represented by n=X,X,X,X in the category titles).
| Giga (10^9) cells per liter (G cells/L) | 21-Day Cycle Placebo | 21-Day Cycle Eltrombopag 100 mg | 28-Day Cycle Placebo | 28-Day Cycle Eltrombopag 100 mg |
|---|---|---|---|---|
| G+Cb, Day 1, n=1,3,0,0 | 296.80 ± NA | 275.00 ± 144.253 | NA ± NA | NA ± NA |
| G+Cb, Day 8, n=1,3,0,0 | 235.00 ± NA | 232.10 ± 77.329 | NA ± NA | NA ± NA |
| G+Cis, Day 1, n=2,6,0,0 | 322.50 ± 82.731 | 526.00 ± 86.408 | NA ± NA | NA ± NA |
| G+Cis, Day 8, n=2,6,0,0 | 326.85 ± 119.006 | 296.75 ± 119.342 | NA ± NA | NA ± NA |
| Gm, Day1, n=0,0,4,9 | NA ± NA | NA ± NA | 309.20 ± 123.133 | 442.79 ± 114.593 |
| Gm, Day8, n=0,0,4,10 | NA ± NA | NA ± NA | 204.20 ± 80.822 | 355.09 ± 148.539 |
| Gm, Day15, n=0,0,3,10 | NA ± NA | NA ± NA | 75.37 ± 18.292 | 164.24 ± 94.905 |
Platelet nadir is defined as the lowest platelet count (from central laboratory data) reported after the first dose of chemotherapy within each cycle. Platelet count nadir is defined for each cycle. For Group A, the chemotherapy cycle consisted of 21 days and for Group B, the chemotherapy cycle consisted of 28 days. Blood samples were collected to estimate platelet nadir count at the following time points: Group A; Days 1, 4, 8, 15 and 17 of Cycles 1 and 2, at Days 1, 4, 8, 15 and 17 of Cycle 3 to 6. Group B; Days 1, 4, 8, 15, 22 and 24 of Cycles 1 to 6. Only those participants available at indicated time points were analyzed (represented by n=X, X, X, X).
| Giga (10^9) cells per liter (G cells/L) | 21-Day Cycle Placebo | 21-Day Cycle Eltrombopag 100 mg | 28-Day Cycle Placebo | 28-Day Cycle Eltrombopag 100 mg |
|---|---|---|---|---|
| Cycle 1, n=3,9,4,10 | 30.67 ± 20.404 | 106.56 ± 113.338 | 60.50 ± 22.664 | 99.00 ± 75.700 |
| Cycle 2, n=2,9,4,10 | 66.00 ± 9.899 | 122.44 ± 115.794 | 103.50 ± 62.952 | 135.50 ± 73.951 |
| Cycle 3, n=2,7,2,7 | 47.00 ± 4.243 | 88.29 ± 71.807 | 78.50 ± 43.134 | 151.00 ± 111.946 |
| Cycle 4, n=2,6,1,7 | 76.50 ± 4.950 | 87.50 ± 79.173 | 86.00 ± NA | 142.86 ± 91.908 |
| Cycle 5, n=1,2,1,4 | 14.00 ± NA | 148.00 ± 182.434 | 75.00 ± NA | 113.25 ± 34.683 |
| Cycle 6, n=1,1,1,4 | 24.00 ± NA | 13.00 ± NA | 110.00 ± NA | 122.75 ± 63.163 |
The average daily area under the platelet-time course was normalized by dividing the area under curve by total duration. This gives an estimated average platelet value over the time period from cycles 2 to 6. For 21-Day Cycle, the chemotherapy cycle consisted of 21 days and for 28-Day Cycle, the chemotherapy cycle consisted of 28 days. Blood samples were collected to estimate thrombocytes at the following time points: 21-Day Cycle; Days 1, 4, 8, 15 and 17 of Cycles 1 to 6. 28-Day Cycle; Days 1, 4, 8, 15, 22 and 24 of Cycles 1 to 6.
| Giga (10^9) cells per liter (G cells/L) | 21-Day Cycle Placebo | 21-Day Cycle Eltrombopag 100 mg) | 28-Day Cycle Placebo | 28-Day Cycle Eltrombopag 100 mg |
|---|---|---|---|---|
| Central Laboratory Average Daily Area Under the Curve Platelet-time Course Across Cycles 2 to 6 in Phase I | 260.97 ± 67.581 | 307.59 ± 95.110 | 183.68 ± 55.366 | 291.18 ± 99.718 |
As per the CTCAE version 4.0, par. with a platelet count \<LLN but \>=75 x 10\^9/L (Gi/L) were considered to have Grade 1 thrombocytopenia; par. with a platelet count \<75Gi/L, but \>=50Gi/L were considered to have Grade 2 thrombocytopenia; par. with a platelet count \<50Gi/L, but \>=25Gi/L were considered to have Grade 3 thrombocytopenia and par. with a platelet count \<25Gi/L were considered to have Grade 4 thrombocytopenia. Blood samples were collected to estimate thrombocytes at the following time points: For Group A, the chemotherapy cycle consisted of 21 days and for Group B, the chemotherapy cycle consisted of 28 days. Blood samples were collected to estimate thrombocytes at the following time points: Group A; Days 1, 4, 8, 15 and 17 of Cycles 1 to 6. Group B; Days 1, 4, 8, 15, 22 and 24 of Cycles 1 to 6. Par. experiencing thrombocytopenia (Platelets \<150Gi/L) at least once within a cycle are presented in the category title as n=X,X,X,X.
| Participants | 21-Day Cycle Placebo | 21-Day Cycle Eltrombopag 100 mg | 28-Day Cycle Placebo | 28-Day Cycle Eltrombopag 100 mg |
|---|---|---|---|---|
| Grade 1, n=3,9,4,10 | 0 | 2 | 1 | 3 |
| Grade 2, n=3,9,4,10 | 0 | 3 | 1 | 4 |
| Grade 3, n=3,9,4,10 | 1 | 1 | 1 | 0 |
| Grade 4, n=3,9,4,10 | 1 | 2 | 0 | 0 |
| Grade 0 / None, n=3,9,4,10 | 1 | 1 | 1 | 3 |
Duration of thrombocytopenia is defined as a period of time in days from the first report of a platelet count with NCI CTCAE Grade 1-4 until the first subsequent report of a platelet count no longer meeting those criteria, regardless of rescue medication usage. It was assessed between Day 1 of Cycle 2 and up to and including any Conclusion/Early Withdrawal visit assigned to the same cycle for participants completing up to 6 cycles, and between Day 1 of Cycle 2 and up to and including the end of Cycle 6 for participants continuing beyond 6 cycles. The chemotherapy cycle for Group A was 21 days and for Group B was 28 days. Blood samples were collected to estimate thrombocytes at the following time points: Group A; Days 1, 4, 8, 15 and 17 of Cycles 2 to 6. Group B; Days 1, 4, 8, 15, 22 and 24 of Cycles 2 to 6.
| Days | 21-Day Cycle Placebo | 21-Day Cycle Eltrombopag 100 mg | 28-Day Cycle Placebo | 28-Day Cycle Eltrombopag 100 mg |
|---|---|---|---|---|
| Maximum Duration of Thrombocytopenia Across Cycles 2 to 6 in Phase I, Estimated Using Central Laboratory Platelet Counts | 11.0 ± 4.24 | 10.6 ± 5.63 | 14.7 ± 7.77 | 13.4 ± 5.06 |
Platelet nadir is defined within each cycle as the lowest platelet count reported after the Day 1 chemotherapy dose. The time taken to reach platelet nadir is defined within each cycle. For Group A, the chemotherapy cycle consisted of 21 days and for Group B, the chemotherapy cycle consisted of 28 days. Blood samples were collected to estimate platelet nadir count at the following time points: Group A; Days 1, 4, 8, 15 and 17 of Cycles 1 to 6. Group B; Days 1, 4, 8, 15, 22 and 24 of Cycles 1 to 6. Only those participants available at indicated time points were analyzed (represented by n=X, X, X, X).
| Days | 21-Day Cycle Placebo | 21-Day Cycle Eltrombopag 100 mg | 28-Day Cycle Placebo | 28-Day Cycle Eltrombopag 100 mg |
|---|---|---|---|---|
| Cycle 1, n=3,9,4,10 | 15.7 ± 0.58 | 11.4 ± 5.53 | 13.8 ± 6.13 | 13.8 ± 4.73 |
| Cycle 2, n=2,9,4,10 | 15.0 ± 1.41 | 12.9 ± 4.68 | 14.0 ± 5.72 | 19.2 ± 4.42 |
| Cycle 3, n=2,7,2,7 | 15.0 ± 1.41 | 12.9 ± 3.02 | 23.5 ± 0.71 | 17.6 ± 4.50 |
| Cycle 4, n=2,6,1,7 | 14.0 ± 0.00 | 13.5 ± 3.33 | 14.0 ± NA | 17.4 ± 6.16 |
| Cycle 5, n=1,2,1,4 | 15.0 ± NA | 11.5 ± 6.36 | 14.0 ± NA | 21.5 ± 1.00 |
| Cycle 6, n=1,1,1,4 | 16.0 ± NA | 14.0 ± NA | 23.0 ± NA | 15.5 ± 5.20 |
Platelet nadir is defined within each cycle as the lowest platelet count reported after the Day 1 chemotherapy dose. Time to recovery (TR) (\>100Gi/L or \>150Gi/L) from platelet nadir is defined within each cycle as the time in days from the platelet nadir to the time at which platelet count returns to \>=100Gi/L or \>=150Gi/L within the same cycle or up to and including Day 1 of the next cycle. For the last cycle in the study, time to recovery was calculated in the same manner but up to and including any Conclusion/Early Withdrawal visit which has been assigned to the same cycle. For Group A, the chemotherapy cycle consisted of 21 days and for Group B, the chemotherapy cycle consisted of 28 days. Blood samples were collected to estimate platelet count at: Group A; Days 1, 4, 8, 15 and 17 of Cycles 1 to 6. Group B; Days 1, 4, 8, 15, 22, and 24 of Cycles 1 to 6. Only those participants available at indicated time points were analyzed (represented by n=X, X, X, X).
| Days | 21-Day Cycle Placebo | 21-Day Cycle Eltrombopag 100 mg | 28-Day Cycle Placebo | 28-Day Cycle Eltrombopag 100 mg |
|---|---|---|---|---|
| TR(<100Gi/L to >=100Gi/L), Cycle 1, n=3,6,4,7 | 5.3 ± 0.58 | 7.2 ± 2.56 | 7.0 ± 0.00 | 7.7 ± 2.87 |
| TR(<100Gi/L to >=100Gi/L), Cycle 2, n=2,5,3,4 | 6.5 ± 2.12 | 6.6 ± 3.65 | 6.0 ± 4.00 | 7.0 ± 5.10 |
| TR(<100Gi/L to >=100Gi/L), Cycle 3, n=1,4,0,2 | 7.0 ± NA | 8.5 ± 3.70 | NA ± NA | 6.0 ± 1.41 |
| TR(<100Gi/L to >=100Gi/L), Cycle 4, n=1,4,1,2 | 2.0 ± NA | 6.5 ± 5.20 | 14.0 ± NA | 5.0 ± 2.83 |
| TR(<100Gi/L to >=100Gi/L), Cycle 5, n=1,1,1,1 | 5.0 ± NA | 5.0 ± NA | 9.0 ± NA | 7.0 ± NA |
| TR(<100Gi/L to >=100Gi/L), Cycle 6, n=0,1,0,0 | NA ± NA | 7.0 ± NA | NA ± NA | NA ± NA |
| TR(<150Gi/L to >=150Gi/L), Cycle 1, n=3,7,4,8 | 5.3 ± 0.58 | 7.6 ± 2.57 | 7.0 ± 0.00 | 8.5 ± 3.46 |
| TR(<150Gi/L to >=150Gi/L), Cycle 2, n=2,4,3,5 | 6.5 ± 2.12 | 7.8 ± 2.99 | 9.0 ± 4.36 | 9.4 ± 4.28 |
| TR(<150Gi/L to >=150Gi/L), Cycle 3, n=1,6,1,5 | 7.0 ± NA | 8.0 ± 2.97 | 7.0 ± NA | 6.2 ± 1.10 |
| TR(<150Gi/L to >=150Gi/L), Cycle 4, n=1,4,1,4 | 8.0 ± NA | 7.8 ± 4.27 | 14.0 ± NA | 8.3 ± 3.95 |
| TR(<150Gi/L to >=150Gi/L), Cycle 5, n=1,0,1,3 | 5.0 ± NA | NA ± NA | 14.0 ± NA | 4.7 ± 2.52 |
| TR(<150Gi/L to >=150Gi/L), Cycle 6, n=0,0,1,0 | NA ± NA | NA ± NA | 5.0 ± NA | NA ± NA |
Dose intensity of chemotherapy is defined as the actual dose of chemotherapy given as a percentage of the scheduled C1D1/C1D8 dose, as applicable, within this study: Cycle Dose Intensity (%) = Total Actual dose (mg/m\^2) within Cycle \*100/ Total Scheduled dose (mg/m\^2) in Cycle 1; wherein Actual Dose (mg/m\^2) = Actual dose (mg)/Body Surface Area reported on electronic case report form (eCRF).
| Dose Intensity (%) | 21-Day Cycle Placebo | 21-Day Cycle Eltrombopag 100 mg | 28-Day Cycle Placebo | 28-Day Cycle Eltrombopag 100 mg |
|---|---|---|---|---|
| G+Cis, Gemcitabine, Cycle 1, n=2,5,0,0 | 100.0 ± 0.00 | 99.8 ± 0.45 | NA ± NA | NA ± NA |
| G+Cis, Gemcitabine, Cycle 2, n=1,5,0,0 | 100.0 ± NA | 92.8 ± 24.83 | NA ± NA | NA ± NA |
| G+Cis, Gemcitabine, Cycle 3, n=1,4,0,0 | 100.0 ± NA | 104.3 ± 8.50 | NA ± NA | NA ± NA |
| G+Cis, Gemcitabine, Cycle 4, n=1,3,0,0 | 100.0 ± NA | 83.3 ± 28.87 | NA ± NA | NA ± NA |
| G+Cis, Cisplatin, Cycle 1, n=2,6,0,0 | 100.0 ± 0.00 | 100.3 ± 1.03 | NA ± NA | NA ± NA |
| G+Cis, Cisplatin, Cycle 2, n=1,6,0,0 | 100.0 ± NA | 102.8 ± 6.05 | NA ± NA | NA ± NA |
| G+Cis, Cisplatin, Cycle 3, n=1,5,0,0 | 100.0 ± NA | 93.8 ± 24.34 | NA ± NA | NA ± NA |
| G+Cis, Cisplatin, Cycle 4, n=1,4,0,0 | 100.0 ± NA | 100.3 ± 0.96 | NA ± NA | NA ± NA |
| G+Cis, Cisplatin, Cycle 5, n=0,1,0,0 | NA ± NA | 50 ± NA | NA ± NA | NA ± NA |
| G+Cb, Gemcitabine, Cycle 1, n=1,2,0,0 | 99.0 ± NA | 100.0 ± 0.00 | NA ± NA | NA ± NA |
| G+Cb, Gemcitabine, Cycle 2, n=1,2,0,0 | 99.0 ± NA | 88.5 ± 17.68 | NA ± NA | NA ± NA |
| G+Cb, Gemcitabine, Cycle 3, n=1,2,0,0 | 99.0 ± NA | 100.0 ± 0.00 | NA ± NA | NA ± NA |
| G+Cb, Gemcitabine, Cycle 4, n=1,2,0,0 | 49.0 ± NA | 99.5 ± 0.71 | NA ± NA | NA ± NA |
| G+Cb, Gemcitabine, Cycle 5, n=1,1,0,0 | 99.0 ± NA | 74.0 ± NA | NA ± NA | NA ± NA |
| G+Cb, Gemcitabine, Cycle 6, n=1,1,0,0 | 99.0 ± NA | 74.0 ± NA | NA ± NA | NA ± NA |
| G+Cb, Carboplatin, Cycle 1, n=1,3,0,0 | 101.0 ± NA | 88.7 ± 14.05 | NA ± NA | NA ± NA |
| G+Cb, Carboplatin, Cycle 2, n=1,3,0,0 | 100.0 ± NA | 103.0 ± 5.20 | NA ± NA | NA ± NA |
| G+Cb, Carboplatin, Cycle 3, n=1,2,0,0 | 93.0 ± NA | 105.0 ± 5.66 | NA ± NA | NA ± NA |
| G+Cb, Carboplatin, Cycle 4, n=1,2,0,0 | 91.0 ± NA | 107.5 ± 2.12 | NA ± NA | NA ± NA |
| G+Cb, Carboplatin, Cycle 5, n=1,1,0,0 | 100.0 ± NA | 71.0 ± NA | NA ± NA | NA ± NA |
| G+Cb, Carboplatin, Cycle 6, n=1,1,0,0 | 87.0 ± NA | 79.0 ± NA | NA ± NA | NA ± NA |
| Gemcitabine, Cycle 1, n=0,0,1,7 | NA ± NA | NA ± NA | 100.0 ± NA | 94.7 ± 6.75 |
| Gemcitabine, Cycle 2, n=0,0,1,7 | NA ± NA | NA ± NA | 100.0 ± NA | 85.0 ± 17.48 |
| Gemcitabine, Cycle 3, n=0,0,1,4 | NA ± NA | NA ± NA | 100.0 ± NA | 79.5 ± 21.44 |
| Gemcitabine, Cycle 4, n=0,0,0,4 | NA ± NA | NA ± NA | NA ± NA | 94.8 ± 4.11 |
| Gemcitabine, Cycle 5, n=0,0,0,3 | NA ± NA | NA ± NA | NA ± NA | 93.7 ± 3.79 |
| Gemcitabine, Cycle 6, n=0,0,0,3 | NA ± NA | NA ± NA | NA ± NA | 72.7 ± 17.01 |
Any delay in a scheduled dose of gemcitabine monotherapy or the combination of gemcitabine plus carboplatin or cisplatin was evaluated for eltrombopag and placebo treated participants.
| Participants | 21-Day Cycle Placebo | 21-Day Cycle Eltrombopag 100 mg | 28-Day Cycle Placebo | 28-Day Cycle Eltrombopag 100 mg |
|---|---|---|---|---|
| Number of Participants With at Least One Delay in Their Scheduled Dose of Chemotherapy in Any Cycle in Phase I | 1 | 2 | 2 | 1 |
AE is any untoward medical occurrence temporally associated with the use of a medicinal product (MP), whether or not considered related to the MP. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a MP. For marketed MPs, this also includes failure to produce expected benefits, abuse, or misuse. SAE event is any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or, is a congenital anomaly/birth defect.
| Participants | Placebo | Eltrombopag 100 mg |
|---|---|---|
| Any AE Pre Therapy | 0 | 1 |
| Any SAE Pre Therapy | 0 | 0 |
| Any AE On Therapy+30 days | 23 | 48 |
| Any SAE On Therapy+30 days | 12 | 16 |
| Any AE Post Therapy | 4 | 2 |
| Any SAE Post Therapy | 2 | 1 |
| Blood/lymphatic system disorders On-therapy+30 day | 21 | 40 |
| Thrombocytopenia On-therapy+30 days | 11 | 19 |
| Anemia On-therapy+30 days | 16 | 26 |
| Neutopenia On-therapy+30 days | 13 | 21 |
| Gastrointestinal disorders On-therapy+30 days | 12 | 25 |
| Blood Creatinine increased On-therapy+30 days | 3 | 2 |
| Vascular discorders On-therapy+30 days | 2 | 6 |
| Cardiac disorders On-therapy+30 days | 1 | 3 |
| Pulmonary embolism On-therapy+30 days | 0 | 1 |
| Portal vein thrombosis On-therapy+30 days | 1 | 0 |
| Deaths On-therapy+30 days | 9 | 13 |
The WHO Bleeding Scale is a measure of bleeding severity with the following grades: Grade 0=no bleeding; Grade 1=petechiae; Grade 2=mild blood loss; Grade 3=gross bleeding; Grade 4=debilitating blood loss. The WHO grades were further classified into the following categories: no bleeding=Grade 0; any bleeding=Grades 1 to 4; no clinically significant bleeding=Grades 0 to 1; clinically significant bleeding=Grades 2 to 4. Baseline is defined as the Day 1 assessment or the latest possible screening assessment. Across Cycles 1-6 included all assessments after first dose of chemotherapy up to the end of Cycle 6. Data exclused for participants taking drugs that affect platelet function or anticoagulants, from the time that the medication was started.
| Participants | Placebo | Eltrombopag 100 mg |
|---|---|---|
| Grade 0 | 11 | 34 |
| Grade 1 | 1 | 0 |
| Grade 2 | 0 | 0 |
| Grade 3 | 0 | 0 |
| Grade 4 | 0 | 1 |
Platelet transfusion was used as a rescue medication for the treatment of thrombocytopenia. Number of participants requiring a platelet transfusion during Cycles 1-6 was summarized and compared between treatment groups using a logistic regression model adjusted for cycle duration. Each cycle included assessments starting at Day 1 of the cycle.
| Participants | Placebo | Eltrombopag 100 mg |
|---|---|---|
| Cycle 1 | 0 | 4 |
| Cycle 2 | 2 | 3 |
| Cycle 3 | 0 | 2 |
| Cycle 4 | 1 | 1 |
| Cycle 5 | 0 | 0 |
| Cycle 6 | 0 | 0 |
Any delay in scheduled dose of gemcitabine monotherapy or the combination of gemcitabine plus carboplatin or cisplatin was evaluated for eltrombopag and placebo treated participants. Number of participants with any delay in dose during 21-day cycle or 28-day cycle, in part 1 or part 2 of the study is summarized and presented. Only those participants who actually received chemotherapy are included for the cisplatin and carboplatin components and all participants are included for the gemcitabine components (represented by n=X,X in the category titles).
| Participants | Placebo | Eltrombopag 100 mg |
|---|---|---|
| Gemcitabine, 21-day cycle, n=11,22 | 5 | 7 |
| Carboplatin, 21-day cycle, n=4,12 | 4 | 5 |
| Cisplatin, 21-day cycle, n=7,9 | 1 | 2 |
| Gemcitabine, 28-day cycle, n=12,30 | 4 | 4 |
Dose reductions are required following potential drug-related toxicities. Number of participants with any dose reduction during 21-day cycle or 28-day cycle, in part 1 or part 2 of the study is summarized and presented. Only participants who actually received chemotherapy were included for the cisplatin and carboplatin components. All participants were included for the gemcitabine components.
| Participants | Placebo | Eltrombopag 100 mg |
|---|---|---|
| Gemcitabine, 21-day cycle, n=11,22 | 7 | 6 |
| Carboplatin, 21-day cycle, n=4,12 | 2 | 2 |
| Cisplatin, 21-day cycle, n=7,9 | 0 | 3 |
| Gemcitabine, 28-day cycle, n=12,30 | 8 | 8 |
Dose intensity of chemotherapy is defined as the actual dose of chemotherapy given as a percentage of the scheduled C1D1/C1D8 dose, as applicable, within this study: cycle Dose Intensity (%) = Total Actual dose (mg/m\^2) within cycle \*100/ Total Scheduled dose (mg/m\^2) in Cycle 1; wherein Actual Dose (mg/m\^2) = Actual dose (mg)/Body Surface Area reported on eCRF. The average chemotherapy dose intensity at Day 1 across Cycles 1 to 6, Day 8 across Cycles 1 to 6 and Day 15 across Cycles 1 to 6 was summarized and compared between treatment groups using an ANCOVA model adjusted for cycle duration and part of the study.
| Dose Intensity (%) | Placebo | Eltrombopag 100 mg |
|---|---|---|
| Cycle 1, n=23,48 | 96.6 ± 10.65 | 97.9 ± 6.19 |
| Cycle 2, n=19,37 | 113.1 ± 33.91 | 97.8 ± 24.99 |
| Cycle 3, n=13,26 | 102.6 ± 42.20 | 98.7 ± 35.77 |
| Cycle 4, n=11,19 | 96.6 ± 27.65 | 90.7 ± 30.00 |
| Cycle 5, n=6,12 | 102.2 ± 31.88 | 81.3 ± 25.39 |
| Cycle 6, n=5,7 | 84.4 ± 21.92 | 65.2 ± 25.48 |
| Cycle 1-6, n=23,49 | 98.5 ± 18.26 | 94.6 ± 15.71 |
Hematology parameters with a related NCI CTCAE (version 4.0) toxicity grading were summarized by toxicity grade at each scheduled assessment, the maximum toxicity grade reached by a participant post-Baseline was summarized. Hematology parameters included Hemoglobin (Hb) increased, Anemia, Lymphocyte count (Lym), platelet count, White Blood Cell count (WBC) and Total Absolute Neutrophil Count (Total ANC). The Baseline value is defined as the value reported immediately prior to the administration of the first dose of chemotherapy in Cycle 1. Post-Baseline is defined as any time after the first dose of chemotherapy in Cycle 1 up to and including all follow-up visits. participants with missing Baseline value were assumed to have normal Baseline value. Only those Participant available at the indicated time points were analyzed (represented by n=X,X in the category titles).
| Participants | Placebo | Eltrombopag 100 mg |
|---|---|---|
| Hb (Increased), Grade 0, n=23,52 | 23 | 52 |
| Hb (Increased), Grade 1, n=23,52 | 0 | 0 |
| Hb (Increased), Grade 2, n=23,52 | 0 | 0 |
| Hb (Increased), Grade 3, n=23,52 | 0 | 0 |
| Hb (Increased), Grade 4, n=23,52 | 0 | 0 |
| Hb (Anemia), Grade 0, n=23,52 | 0 | 4 |
| Hb (Anemia), Grade 1, n=23,52 | 4 | 16 |
| Hb (Anemia), Grade 2, n=23,52 | 13 | 16 |
| Hb (Anemia), Grade 3, n=23,52 | 6 | 16 |
| Hb (Anemia), Grade 4, n=23,52 | 0 | 0 |
| Lym (Increased), Grade 0, n=23,52 | 22 | 47 |
| Lym (Increased), Grade 1, n=23,52 | 0 | 0 |
| Lym (Increased), Grade 2, n=23,52 | 1 | 2 |
| Lym (Increased), Grade 3, n=23,52 | 0 | 1 |
| Lym (Increased), Grade 4, n=23,52 | 0 | 0 |
| Lym (Decreased), Grade 0, n=23,52 | 1 | 7 |
| Lym (Decreased), Grade 1, n=23,52 | 3 | 10 |
| Lym (Decreased), Grade 2, n=23,52 | 8 | 14 |
| Lym (Decreased), Grade 3, n=23,52 | 9 | 16 |
| Lym (Decreased), Grade 4, n=23,52 | 2 | 3 |
| Total ANC, Grade 0, n=23,52 | 4 | 16 |
| Total ANC, Grade 1, n=23,52 | 1 | 4 |
| Total ANC, Grade2, n=23,52 | 3 | 17 |
| Total ANC, Grade 3, n=23,52 | 10 | 10 |
| Total ANC, Grade 4, n=23,52 | 5 | 3 |
| Platelet count, Grade 0, n=23,52 | 0 | 7 |
| Platelet count, Grade 1, n=23,52 | 4 | 9 |
| Platelet count, Grade 2, n=23,52 | 3 | 9 |
| Platelet count, Grade 3, n=23,52 | 6 | 15 |
| Platelet count, Grade 4, n=23,52 | 10 | 12 |
| WBC count, Grade 0, n=23,52 | 4 | 14 |
| WBC count, Grade 1, n=23,52 | 3 | 10 |
| WBC count, Grade 2, n=23,52 | 8 | 17 |
| WBC count, Grade 3, n=23,52 | 6 | 11 |
| WBC count, Grade 4, n=23,52 | 2 | 0 |
Clinical chemistry laboratory parameters with a related CTCAE (version 4.0) toxicity grading were summarized by toxicity grade at each scheduled assessment. Worst-case grade change of the laboratory parameters at anytime post-Baseline is presented as "Any grade increase", "Increase to Grade 3 or Grade 4". Clinical chemistry laboratory parameters included Albumin (Al), creatinine, AST, ALT, ALP, TB, Calcium hypercalcemia (CaHy)/hypocalcemia (CaHo), Glucose hyperglycemia (GluHy)/hypoglycemia (GluHo), Potassium hypernatremia (KHy)/hyponatremia (KHo) and Sodium hypernatremia (NaHy)/hyponatremia (NaHo). The Baseline value is defined as the value reported immediately prior to the administration of the first dose of chemotherapy in Cycle 1. Post-Baseline is defined as any time after the first dose of chemotherapy in Cycle 1 up to and including all follow-up visits. Only those Participant available at the indicated time points were analyzed (represented by n=X,X in the category titles).
| participants | Placebo | Eltrombopag 100 mg |
|---|---|---|
| Al, Any grade increase, n=23,51 | 10 | 22 |
| Al, Increase to Grade 3, n=23,51 | 0 | 2 |
| Al, Increase to Grade 4, n=23,51 | 0 | 0 |
| ALP, Any grade increase, n=23,52 | 11 | 16 |
| ALP, Increase to Grade 3, n=23,52 | 1 | 2 |
| ALP, Increase to Grade 4, n=23,52 | 0 | 0 |
| ALT, Any grade increase, n=23,52 | 12 | 16 |
| ALT, Increase to Grade 3, n=23,52 | 3 | 2 |
| ALT, Increase to Grade 4, n=23,52 | 0 | 0 |
| AST, Any grade increase, n=23,52 | 11 | 15 |
| AST, Increase to Grade 3, n=23,52 | 3 | 2 |
| AST, Increase to Grade 4, n=23,52 | 0 | 0 |
| TB, Any grade increase, n=23,52 | 5 | 11 |
| TB, Increase to Grade 3, n=23,52 | 3 | 2 |
| TB, Increase to Grade 4, n=23,52 | 0 | 0 |
| CaHy, Any grade increase, n=23,51 | 0 | 1 |
| CaHy, Increase to Grade 3, n=23,51 | 0 | 0 |
| CaHy, Increase to Grade 4, n=23,51 | 0 | 0 |
| CaHo, Any grade increase, n=23,51 | 3 | 10 |
| CaHo, Increase to Grade 3, n=23,51 | 1 | 2 |
| CaHo, Increase to Grade 4, n=23,51 | 0 | 0 |
| Creatinine, Any grade increase, n=23,52 | 5 | 11 |
| Creatinine, Increase to Grade 3, n=23,52 | 1 | 0 |
| Creatinine, Increase to Grade 4, n=23,52 | 0 | 0 |
| GluHy, Any grade increase, n=23,52 | 13 | 31 |
| GluHy, Increase to Grade 3, n=23,52 | 2 | 3 |
| GluHy, Increase to Grade 4, n=23,52 | 0 | 0 |
| GluHo, Any grade increase, n=23,52 | 2 | 4 |
| GluHo, Increase to Grade 3, n=23,52 | 0 | 0 |
| GluHo, Increase to Grade 4, n=23,52 | 1 | 0 |
| NaHy, Any grade increase, n=23,52 | 0 | 2 |
| NaHy, Increase to Grade 3, n=23,52 | 0 | 0 |
| NaHy, Increase to Grade 4, n=23,52 | 0 | 0 |
| NaHo, Any grade increase, n=23,52 | 4 | 15 |
| NaHo, Increase to Grade 3, n=23,52 | 1 | 1 |
| NaHo, Increase to Grade 4, n=23,52 | 0 | 0 |
| KHy, Any grade increase, n=23,52 | 4 | 10 |
| KHy, Increase to Grade 3, n=23,52 | 1 | 1 |
| KHy, Increase to Grade 4, n=23,52 | 0 | 0 |
| KHo, Any grade increase, n=23,52 | 5 | 11 |
| KHo, Increase to Grade 3, n=23,52 | 1 | 4 |
| KHo, Increase to Grade 4, n=23,52 | 0 | 1 |
Number of participants with at least 1 assessment of change from Baseline in creatinine, with increase \>=26.5 UMOL/L are presented. The Baseline value is defined as the value reported immediately prior to the administration of the first dose of IP.
| participants | Placebo | Eltrombopag 100 mg |
|---|---|---|
| Number of Participants With Change From Baseline in Creatinine of >=26.5 UMOL/L in Phase II | 5 | 11 |
ECOG-Zubrod scores for the Performance Status were defined as follows: 0: Fully active, 1: Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, 2: Ambulatory and capable of all self-care but unable to carry out any work activities, 3: Capable of only limited self-care, 4: Completely disabled, 5 and Unknown: Dead. The data is presented for the participants with the ECOG performance score at different time points during the study. Only those participants available at the indicated time points were analyzed (represented by n=X,X in the category titles).
| participants | Placebo | Eltrombopag 100 mg |
|---|---|---|
| Screening, Score 0, n=23,52 | 3 | 19 |
| Screening, Score 1, n=23,52 | 19 | 32 |
| Screening, Score 2, n=23,52 | 1 | 1 |
| C1D1, Score 0, n=23,49 | 4 | 20 |
| C1D1, Score 1, n=23,49 | 17 | 28 |
| C1D1, Score 2, n=23,49 | 0 | 1 |
| C1D1, Unknown, n=23,49 | 2 | 0 |
| C2D1, Score 0, n=19,36 | 4 | 16 |
| C2D1, Score 1, n=19,36 | 13 | 18 |
| C2D1, Score 2, n=19,36 | 2 | 2 |
| C3D1, Score 0, n=13,27 | 3 | 9 |
| C3D1, Score 1, n=13,27 | 9 | 16 |
| C3D1, Score 2, n=13,27 | 1 | 2 |
| C4D1, Score 0, n=11,19 | 4 | 8 |
| C4D1, Score 1, n=11,19 | 7 | 10 |
| C4D1, Score 2, n=11,19 | 0 | 1 |
| C5D1, Score 0, n=6,12 | 2 | 5 |
| C5D1, Score 1, n=6,12 | 4 | 6 |
| C5D1, Score 2, n=6,12 | 0 | 1 |
| C6D1, Score 0, n=6,7 | 2 | 3 |
| C6D1, Score 1, n=6,7 | 4 | 4 |
| C7D1, Score 0, n=3,2 | 1 | 0 |
| C7D1, Score 1, n=3,2 | 2 | 2 |
| C8D1, Score 0, n=2,1 | 1 | 0 |
| C8D1, Score 1, n=2,1 | 1 | 1 |
| C9D1, Score 1, n=2,1 | 2 | 1 |
| C10D1, Score1 n=2,0 | 2 | 0 |
| C11D1, Score 1, n=2,0 | 1 | 0 |
| C11D1, Score 2, n=2,0 | 1 | 0 |
| C12D1, Score 1, n=2,0 | 2 | 0 |
| C13D1, Score 0, n=2,0 | 1 | 0 |
| C13D1, Score 1, n=2,0 | 1 | 0 |
| C14D1, Score 0, n=2,0 | 1 | 0 |
| C14D1, Score 1, n=2,0 | 1 | 0 |
| C15D1, Score 1, n=2,0 | 2 | 0 |
| C16D1, Score 0, n=1,0 | 1 | 0 |
| C17D1, Score 2, n=1,0 | 1 | 0 |
A single safety 12-lead ECG was performed using a standard 12-lead ECG machine at screening and 2 to 6 hours post-dose on C1D4. Change in ECG findings were categorized as 'Clinically significant change (CSC): favorable', 'No change or insignificant change' or 'Clinically significant change (CSC): unfavorable' as determined by the investigator. The Baseline value is defined as the value reported immediately prior to the administration of the first dose of investigational product. Only those participants available at the indicated time points were analyzed (represented by n=X,X in the category titles).
| participants | Placebo | Eltrombopag 100 mg |
|---|---|---|
| CSC favorable, n=22,45 | 0 | 2 |
| No change or insignificant change, n=22,45 | 20 | 42 |
| CSC: unfavorable, n=22,45 | 2 | 1 |
Scheduled pre-chemotherapy platelet count is defined within each cycle as the platelet count assessment on which the decision to give or delay chemotherapy was made. This was averaged for each subject across cycles 1 to 6 and a natural log transformation was applied to the average. The log-transformed values were compared between eltrombopag and placebo groups using an analysis of covariance (ANCOVA) model adjusting for cycle duration (21-day vs. 28-day), baseline loge(platelet count) and part of study (part 1 or 2 of phase II). The number of participants analyzed is the number with a Day 8 scheduled platelet count.
| Giga (10^9) cells per liter (G cells/L) | Placebo | Eltrombopag 100 mg |
|---|---|---|
| Mean Day 8 Scheduled Pre-chemotherapy Platelet Counts Evaluated Across Cycles 1 to 6 in Phase II | 162.18 ± 74.2 | 180.65 ± 59.1 |
Scheduled pre-chemotherapy platelet count is defined within each cycle as the platelet count assessment on which the decision to give or delay chemotherapy was made. This was averaged for each subject across cycles 1 to 6 and a natural log transformation was applied to the average. The log-transformed values were compared between eltrombopag and placebo groups using an analysis of covariance (ANCOVA) model adjusting for cycle duration (21-day vs. 28-day), baseline loge(platelet count) and part of study (part 1 or 2 of phase II). The number of participants analyzed is the number with a Day 15 scheduled platelet count.
| Giga (10^9) cells per liter (G cells/L) | Placebo | Eltrombopag 100 mg |
|---|---|---|
| Mean Day 15 Scheduled Pre-chemotherapy Platelet Counts Evaluated Across Cycles 1 to 6 in Phase II | 95.10 ± 23.3 | 95.29 ± 52.1 |
Within-subject platelet count for each par. was calculated by summing up the visit platelet counts from each of Cycles 1 to 6 and dividing it by the number of cycles in which the par. had data. The average within a treatment group was calculated by summing up the values from each par. within the treatment 21-day cycle dividing it by the number of par. These platelet counts are different from the pre-chemotherapy platelet counts for cycles where the chemotherapy dose was delayed. Average within-subject central laboratory platelet count prior to scheduled chemotherapy across Cycles 1 to 6 are summarized. Blood samples were collected on Day 1 and 8 of Cycles 1 to 6 for 21-day cycle and on Day 1, 8 and 15 from Cycles 1 to 6 for 28-day cycle to estimate the average within subject platelet count prior to scheduled chemotherapy. Only those participants available at the indicated time points were analyzed (represented by n=X,X in the category titles).
| Giga (10^9) cells per liter (G cells/L) | Placebo | Eltrombopag 100 mg |
|---|---|---|
| Day1, n=23,48 | 221.0 ± 128.23 | 272.9 ± 120.92 |
| Day 8, n=20,42 | 201.0 ± 143.75 | 207.4 ± 110.93 |
| Day 15, n=9,22 | 97.5 ± 24.82 | 106.7 ± 54.73 |
Platelet nadir is defined as the lowest platelet count reported after the first dose of chemotherapy within each cycle. Platelet count nadir is defined for each cycle. Blood samples were collected to estimate platelet nadir count at the following time points: 21-day cycle; Day 1, Day 4, Day 8, Day 15 and Day 17 of Cycles 1 to 6. 28-day cycle; Day 1, Day 4, Day 8, Day 15, Day 22, Day 24 of Cycles 1 to 6. Only those participants available at indicated time points were analyzed (represented by n=X, X).
| Giga (10^9) cells per liter (G cells/L) | Placebo | Eltrombopag 100 mg |
|---|---|---|
| Cycle 1, n=23,48 | 68.3 ± 47.74 | 77.2 ± 76.43 |
| Cycle 2, n=19,37 | 61.5 ± 35.82 | 68.5 ± 48.92 |
| Cycle 3, n=13,26 | 71.6 ± 53.80 | 84.7 ± 60.03 |
| Cycle 4, n=11, 19 | 89.7 ± 116.73 | 86.9 ± 56.11 |
| Cycle 5, n=6,11 | 51.7 ± 12.23 | 83.0 ± 58.63 |
| Cycle 6, n=5,5 | 69.6 ± 62.76 | 136.6 ± 151.88 |
The average daily area under the platelet-time course was normalized by dividing the area under curve by total duration. This gives an estimated average platelet value over the time period from cycles 1 to 6. Blood samples were collected to estimate platelet count at the following time points: 21-day cycle; Days 1, 4, 8, 15 and 17 of Cycles 1 to 6. 28-day cycle; Days 1, 4, 8, 15, 22 and 24 of Cycles 1 to 6.
| Giga (10^9) cells per liter (G cells/L) | Placebo | Eltrombopag 100 mg |
|---|---|---|
| Average Daily Area Under the Platelet-time Course Across Cycles 1 to 6 in Phase II | 153.00 ± 96.079 | 189.48 ± 79.583 |
As per the CTCAE version 4.0, participants with a platelet count \<LLN but \>=75 x 10\^9/L (Gi/L) were considered to have Grade 1 thrombocytopenia; participants with a platelet count \<75Gi/L, but \>=50Gi/L were considered to have Grade 2 thrombocytopenia; participants with a platelet count \<50Gi/L, but \>=25Gi/L were considered to have Grade 3 thrombocytopenia and participants with a platelet count \<25Gi/L were considered to have Grade 4 thrombocytopenia. Blood samples were collected to estimate thrombocytes at the following time points: 21-day cycle; Days 1, 4, 8, 15 and 17 of Cycles 1 to 6. 28-day cycle; Days 1, 4, 8, 15, 22 and 24 of Cycles 1 to 6. Participants experiencing thrombocytopenia(Platelets \<150Gi/L) at least once within cycle are presented in the category title as n=X,X.
| Participants | Placebo | Eltrombopag 100 mg |
|---|---|---|
| Grade 1 | 4 | 9 |
| Grade 2 | 3 | 9 |
| Grade 3 | 8 | 15 |
| Grade 4 | 8 | 12 |
| None | 0 | 5 |
Duration of thrombocytopenia is defined as a period of time in days from the first report of a platelet count with NCI CTCAE Grade 1-4 until the first subsequent report of a platelet count no longer meeting those criteria, regardless of rescue medication usage. It was assessed between Day 1 of Cycle 2 and up to and including any Conclusion/Early Withdrawal visit assigned to the same cycle for participants completing up to 6 cycles, and between Day 1 of Cycle 2 and up to and including the end of Cycle 6 for participants continuing beyond 6 cycles. The chemotherapy cycle for 21-day cycle was 21 days and for 28-day cycle was 28 days. Blood samples were collected to estimate thrombocytes at the following time points: 21-day cycle; Days 1, 4, 8, 15 and 17 of Cycles 2 to 6. 28-day cycle; Days 1, 4, 8, 15, 22 and 24 of Cycles 2 to 6.
| Days | Placebo | Eltrombopag 100 mg |
|---|---|---|
| Maximum Duration of Thrombocytopenia Across Cycles 1 to 6 in Phase II | 32.6 ± 20.31 | 23.5 ± 18.68 |
Platelet nadir is defined within each cycle as the lowest platelet count reported after the Day 1 chemotherapy dose. The time taken to reach platelet nadir is defined within each cycle. Blood samples were collected to estimate platelet nadir count at the following time points: 21-day cycle; Days 1, 4, 8, 15 and 17 of Cycles 1 to 6. 28-day cycle; Days 1, 4, 8, 15, 22 and 24 of Cycles 1 to 6. Only those participants available at indicated time points were analyzed (represented by n=X, X).
| Days | Placebo | Eltrombopag 100 mg |
|---|---|---|
| Cycle 1, n=23,48 | 14.7 ± 4.85 | 15.7 ± 6.12 |
| Cycle 2, n=19,37 | 15.1 ± 4.41 | 15.4 ± 3.62 |
| Cycle 3, n=13,26 | 15.8 ± 5.64 | 14.3 ± 4.76 |
| Cycle 4, n=11,19 | 15.4 ± 5.48 | 14.7 ± 5.19 |
| Cycle 5, n=6,11 | 15.5 ± 6.38 | 13.8 ± 4.45 |
| Cycle 6, n=5,5 | 13.6 ± 7.37 | 10.4 ± 6.31 |
| Cycle 7,n=2,2 | 15.0 ± 0.00 | 7.5 ± 0.71 |
| Cycle 8, n=2,1 | 12.5 ± 3.54 | 8.0 ± NA |
| Cycle 9, n=2,0 | 12.5 ± 3.54 | NA ± NA |
Platelet nadir is defined within each cycle as the lowest platelet count reported after the Day 1 chemotherapy dose. TR (\>100Gi/L or \>150Gi/L) from platelet nadir is defined within each cycle as the time in days from the platelet nadir to the time at which platelet count returns to \>=100Gi/L or \>=150Gi/L within the same cycle or up to and including Day 1 of the next cycle. For the last cycle in the study, time to recovery was calculated in the same manner but up to and including any Conclusion/Early Withdrawal visit which has been assigned to the same cycle. Blood samples were collected to estimate platelet count at: 21-day cycle; Days 1, 4, 8, 15 and 17 of Cycles 1 to 6. 28-day cycle; Days 1, 4, 8, 15, 22, and 24of Cycles 1 to 6. Time to recover censored if platelet count did not return to \>=100/150 Gi/L. Censored results are excluded from calculation of summary statistics. Only those participants available at indicated time points were analyzed (represented by n=X, X).
| Days | Placebo | Eltrombopag 100 mg |
|---|---|---|
| TR(<100Gi/L to >=100Gi/L), Cycle 1, n=17, 32 | 8.1 ± 3.15 | 8.5 ± 3.70 |
| TR(<150Gi/L to >=150Gi/L), Cycle 1, n=12, 29 | 9.3 ± 3.89 | 9.1 ± 3.26 |
| TR(<100Gi/L to >=100Gi/L), Cycle 2, n=13, 24 | 9.9 ± 3.64 | 8.3 ± 2.56 |
| TR(<150Gi/L to >=150Gi/L), Cycle 2, n=11, 21 | 10.5 ± 4.50 | 9.0 ± 3.31 |
| TR(<100Gi/L to >=100Gi/L), Cycle 3, n=9, 12 | 10.1 ± 5.01 | 8.8 ± 3.16 |
| TR(<150Gi/L to >=150Gi/L), Cycle 3, n=7, 14 | 10.4 ± 5.74 | 9.6 ± 3.43 |
| TR(<100Gi/L to >=100Gi/L), Cycle 4, n=8, 10 | 10.0 ± 5.63 | 10.9 ± 4.77 |
| TR(<150Gi/L to >=150Gi/L), Cycle 4, n=5, 11 | 10.2 ± 6.65 | 10.6 ± 5.39 |
| TR(<100Gi/L to >=100Gi/L), Cycle 5, n=5,6 | 7.8 ± 1.10 | 8.8 ± 4.79 |
| TR(<150Gi/L to >=150Gi/L), Cycle 5, n=2,4 | 8.0 ± 0.00 | 7.3 ± 1.50 |
| TR(<100Gi/L to >=100Gi/L), Cycle 6, n=2,2 | 10.5 ± 6.36 | 8.5 ± 0.71 |
| TR(<150Gi/L to >=150Gi/L), Cycle 6, n=2,1 | 10.5 ± 6.36 | 8.0 ± NA |
| TR(<100Gi/L to >=100Gi/L), Cycle 7, n=1,1 | 15.0 ± NA | 22.0 ± NA |
| TR(<150Gi/L to >=150Gi/L), Cycle 7, n=1,1 | 15.0 ± NA | 22.0 ± NA |
| TR(<100Gi/L to >=100Gi/L), Cycle 8, n=1,1 | 14.0 ± 1.41 | 20.0 ± NA |
| TR(<150Gi/L to >=150Gi/L), Cycle 8, n=1,0 | 15.0 ± NA | NA ± NA |
| TR(<100Gi/L to >=100Gi/L), Cycle 9, n=2, | 14.0 ± 11.31 | NA ± NA |
| TR(<150Gi/L to >=150Gi/L), Cycle 9, n=0, | NA ± NA | NA ± NA |
Collected over AEs and SAEs were collected from Cycle 1, Day 1 for Phase I; and from the time the first dose of investigational product (IP) is administered for Phase II; up to 30 days following discontinuation of IP.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase I: 21-Day Cycle Placebo | — | 1/3 (33.3%) | 3/3 (100%) |
| Phase I: 21-Day Cycle Eltrombopag | — | 5/9 (55.6%) | 9/9 (100%) |
| Phase I: 28-Day Cycle Placebo | — | 1/4 (25%) | 4/4 (100%) |
| Phase I: 28-Day Cycle Eltrombopag 100 mg | — | 2/10 (20%) | 10/10 (100%) |
| Phase II: Placebo | — | 13/23 (56.5%) | 22/23 (95.7%) |
| Phase II: Eltrombopag | — | 17/52 (32.7%) | 47/52 (90.4%) |
| Event | Phase I: 21-Day Cycle Placebo | Phase I: 21-Day Cycle Eltrombopag | Phase I: 28-Day Cycle Placebo | Phase I: 28-Day Cycle Eltrombopag 100 mg | Phase II: Placebo | Phase II: Eltrombopag |
|---|---|---|---|---|---|---|
| PneumoniaInfections and infestations | 1/3 | 0/9 | 0/4 | 0/10 | 0/23 | 3/52 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 1/3 | 0/9 | 0/4 | 0/10 | 0/23 | 1/52 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 1/3 | 0/9 | 0/4 | 0/10 | 0/23 | 0/52 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 0/3 | 0/9 | 1/4 | 0/10 | 0/23 | 1/52 |
| OliguriaRenal and urinary disorders | 0/3 | 0/9 | 1/4 | 0/10 | 0/23 | 0/52 |
| Deep vein thrombosisVascular disorders | 0/3 | 2/9 | 0/4 | 0/10 | 0/23 | 0/52 |
| NauseaGastrointestinal disorders | 0/3 | 1/9 | 0/4 | 0/10 | 0/23 | 1/52 |
| VomitingGastrointestinal disorders | 0/3 | 1/9 | 0/4 | 0/10 | 0/23 | 1/52 |
| Device damageGeneral disorders | 0/3 | 1/9 | 0/4 | 0/10 | 0/23 | 0/52 |
| CholangitisHepatobiliary disorders | 0/3 | 1/9 | 0/4 | 0/10 | 0/23 | 0/52 |
| Event | Phase I: 21-Day Cycle Placebo | Phase I: 21-Day Cycle Eltrombopag | Phase I: 28-Day Cycle Placebo | Phase I: 28-Day Cycle Eltrombopag 100 mg | Phase II: Placebo | Phase II: Eltrombopag |
|---|---|---|---|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 3/3 | 5/9 | 2/4 | 6/10 | 13/23 | 21/52 |
| ThrombocytopeniaBlood and lymphatic system disorders | 3/3 | 3/9 | 4/4 | 5/10 | 10/23 | 18/52 |
| AnaemiaBlood and lymphatic system disorders | 1/3 | 4/9 | 3/4 | 5/10 | 15/23 | 24/52 |
| LeukopeniaBlood and lymphatic system disorders | 2/3 | 2/9 | 2/4 | 3/10 | 2/23 | 9/52 |
| ThrombocytosisBlood and lymphatic system disorders | 2/3 | 2/9 | 1/4 | 2/10 | 2/23 | 4/52 |
| NauseaGastrointestinal disorders | 1/3 | 6/9 | 1/4 | 1/10 | 2/23 | 10/52 |
| FatigueGeneral disorders | 1/3 | 1/9 | 2/4 | 3/10 | 3/23 | 13/52 |
| Oedema peripheralGeneral disorders | 0/3 | 1/9 | 2/4 | 2/10 | 1/23 | 5/52 |
| PyrexiaGeneral disorders | 1/3 | 1/9 | 2/4 | 0/10 | 4/23 | 3/52 |
| DizzinessNervous system disorders | 0/3 | 0/9 | 2/4 | 1/10 | 2/23 | 1/52 |
| Age, Continuous(Years) | Phase I: 21-Day Cycle Placebo | Phase I: 21-Day Cycle Eltrombopag 100 mg | Phase I: 28-Day Cycle Placebo | Phase I: 28-Day Cycle Eltrombopag 100 mg | Phase II: Placebo | Phase II: Eltrombopag 100 mg | Total |
|---|---|---|---|---|---|---|---|
| Mean | 53.3 ± 3.79 | 53.8 ± 11.27 | 61.8 ± 22.82 | 65.6 ± 8.41 | 64.4 ± 9.96 | 66.3 ± 8.98 | 64.1 ± 10.56 |
| Sex: Female, Male(Participants) | Phase I: 21-Day Cycle Placebo | Phase I: 21-Day Cycle Eltrombopag 100 mg | Phase I: 28-Day Cycle Placebo | Phase I: 28-Day Cycle Eltrombopag 100 mg | Phase II: Placebo | Phase II: Eltrombopag 100 mg | Total |
|---|---|---|---|---|---|---|---|
| Female | 1 | 7 | 3 | 3 | 13 | 23 | 50 |
| Male | 2 | 2 | 1 | 7 | 10 | 29 | 51 |
| Race/Ethnicity, Customized(Participants) | Phase I: 21-Day Cycle Placebo | Phase I: 21-Day Cycle Eltrombopag 100 mg | Phase I: 28-Day Cycle Placebo | Phase I: 28-Day Cycle Eltrombopag 100 mg | Phase II: Placebo | Phase II: Eltrombopag 100 mg | Total |
|---|---|---|---|---|---|---|---|
| African American/African Heritage | 1 | 1 | 0 | 0 | 1 | 0 | 3 |
| White | 2 | 8 | 3 | 8 | 22 | 52 | 95 |
| Central/South Asian Heritage | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Japanese/East Asian Heritage/South East Asian | 0 | 0 | 0 | 2 | 0 | 0 | 2 |
The record gives a start of Jun 2010, a primary completion of Jan 2015 and a completion of Mar 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2016, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eltrombopag